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A B S T R A C T
Background
Despite medical therapies and surgical interventions for Parkinson’s disease (PD), patients develop progressive disability. Physiotherapy
aims to maximise functional ability and minimise secondary complications through movement rehabilitation within a context of
education and support for the whole person. The overall aim is to optimise independence, safety, and well-being, thereby enhancing
quality of life.
Objectives
To assess the effectiveness of physiotherapy intervention compared with no intervention in patients with PD.
Search methods
We identified relevant trials by conducting electronic searches of numerous literature databases (e.g. MEDLINE, EMBASE) and trial
registers, and by handsearching major journals, abstract books, conference proceedings, and reference lists of retrieved publications.
The literature search included trials published up to the end of January 2012.
Selection criteria
Randomised controlled trials of physiotherapy intervention versus no physiotherapy intervention in patients with PD.
Data collection and analysis
Two review authors independently extracted data from each article. We used standard meta-analysis methods to assess the effectiveness
of physiotherapy intervention compared with no physiotherapy intervention. Trials were classified into the following intervention
comparisons: general physiotherapy, exercise, treadmill training, cueing, dance, and martial arts. We used tests for heterogeneity to
assess for differences in treatment effect across these different physiotherapy interventions.
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Main results
We identified 39 trials with 1827 participants. We considered the trials to be at a mixed risk of bias as the result of unreported allocation
concealment and probable detection bias. Compared with no intervention, physiotherapy significantly improved the gait outcomes of
speed (mean difference 0.04 m/s, 95% confidence interval (CI) 0.02 to 0.06, P = 0.0002); two- or six-minute walk test (13.37 m, 95%
CI 0.55 to 26.20, P = 0.04) and Freezing of Gait questionnaire (-1.41, 95% CI -2.63 to -0.19, P = 0.02); functional mobility and
balance outcomes of Timed Up & Go test (-0.63 s, 95% CI -1.05 to -0.21, P = 0.003), Functional Reach Test (2.16 cm, 95% CI 0.89
to 3.43, P = 0.0008), and Berg Balance Scale (3.71 points, 95% CI 2.30 to 5.11, P < 0.00001); and clinician-rated disability using the
Unified Parkinson’s Disease Rating Scale (UPDRS) (total -6.15 points, 95% CI-8.57 to -3.73, P < 0.00001; activities of daily living: -
1.36, 95% CI -2.41 to -0.30, P = 0.01; and motor: -5.01, 95% CI -6.30 to -3.72, P < 0.00001). No difference between arms was noted
in falls (Falls Efficacy Scale: -1.91 points, 95% CI -4.76 to 0.94, P = 0.19) or patient-rated quality of life (PDQ-39 Summary Index:
-0.38 points, 95% CI -2.58 to 1.81, P = 0.73). One study reported that adverse events were rare; no other studies reported data on
this outcome. Indirect comparisons of the different physiotherapy interventions revealed no evidence that the treatment effect differed
across physiotherapy interventions for any of the outcomes assessed.
Authors’ conclusions
Benefit for physiotherapy was found in most outcomes over the short term (i.e. < 3 months) but was significant only for speed, two-
or six-minute walk test, Freezing of Gait questionnaire, Timed Up & Go, Functional Reach Test, Berg Balance Scale, and clinician-
rated UPDRS. Most of the observed differences between treatments were small. However, for some outcomes (e.g. speed, Berg Balance
Scale, UPDRS), the differences observed were at, or approaching, what are considered minimal clinically important changes. These
benefits should be interpreted with caution because the quality of most of the included trials was not high. Variation in measurements
of outcome between studies meant that our analyses include a small proportion of the participants recruited.
This review illustrates that a wide range of approaches are employed by physiotherapists to treat patients with PD. However, no evidence
of differences in treatment effect was noted between the different types of physiotherapy interventions being used, although this was
based on indirect comparisons. A consensus menu of ’best practice’ physiotherapy is needed, as are large, well-designed randomised
controlled trials undertaken to demonstrate the longer-term efficacy and cost-effectiveness of ’best practice’ physiotherapy in PD.
P L A I N L A N G U A G E S U M M A R Y
Physiotherapy for treatment of Parkinson’s disease
In spite of various medical and surgical treatments for Parkinson’s disease (PD), patients gradually develop significant physical problems.
Physiotherapists aim to enable people with PD to maintain their maximum level of mobility, activity, and independence by monitoring
their condition and targeting appropriate treatment. A range of approaches to movement rehabilitation are used, which aim to enhance
quality of life by maximising physical ability and minimising problems related to Parkinson’s over the whole course of the disease.
Only randomised controlled trials were included in this review. In these studies,a group of participants were given physiotherapy
intervention and were compared with another group of participants, who did not receive physiotherapy. Participants were assigned to
a group in random fashion so a fair test was established. Thirty-nine randomised trials involving 1827 participants were identified as
suitable for this review. The quality of the trials was not high because in many, methods were not reported adequately and blinding was
not feasible. These trials assessed various physiotherapy interventions, so the trials were grouped according to the type of intervention
being used (i.e. general physiotherapy, exercise, treadmill training, cueing, dance, or martial arts).
Improvement in all walking outcomes (except the 10- or 20-metre walk test) was noted with physiotherapy intervention. However, these
improvements were significant only for walking speed, walking endurance, and freezing of gait. Mobility and balance also improved
with a physiotherapy intervention, with significant improvements reported in one test of mobility (the Timed Up & Go test, which
times how long it takes a person to get up from a chair, walk a certain distance, then walk back to the chair and sit down) and in
two tests of balance (one assessing how far a person can reach before he or she loses balance (Functional Reach Test) and another
assessing multiple aspects of balance (Berg Balance Scale)). Clinician-rated disability, using the Unified Parkinson’s Disease Rating
Scale (UPDRS), was also improved with physiotherapy intervention. No difference was observed between the two groups in falls or
patient-rated quality of life. One study reported that adverse events were rare; no other studies reported data on this outcome. When
the different physiotherapy interventions were compared, no evidence suggested that treatment effect differed across the physiotherapy
interventions for any of the outcomes assessed.
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This review provides evidence of the short-term benefit of physiotherapy for the treatment of PD. Although most observed differences
were small, improvements in walking speed, balance with the Berg Balance Scale, and clinician-rated disability using the UPDRS were
of a size that patients may consider them to be important. These benefits should be interpreted with caution because of the quality of
the included trials, and the lack of common assessment of treatment effects. This affected the quantity of data that we could use for
analysis.
B A C K G R O U N D
Parkinson’s disease (PD) is a complex neurodegenerative disor-
der (Rubenis 2007) with wide reaching implications for patients
and their families. Although disability can occur at all stages of
the disease (Deane 2001a), PD is progressive in nature, and so
patients face increased difficulties with activities of daily living
(ADL) (Kwakkel 2007) and various aspects of mobility such as
gait, transfers, balance, and posture (Keus 2007b). Ultimately, this
leads to decreased independence, inactivity, and social isolation
(Keus 2007b), resulting in reduced quality of life (Schrag 2000).
The management of PD has traditionally centred on drug ther-
apy, with levodopa viewed as the ’gold standard’ treatment (Rascol
2002).However, evenwith optimalmedicalmanagement, patients
with PD experience deterioration in body function, daily activi-
ties, and participation (Nijkrake 2007). For this reason, support
has been increasing for the inclusion of rehabilitation therapies
as an adjuvant to pharmacological and neurosurgical treatment
(Gage 2004; Nijkrake 2007), and a call for the move towards
multidisciplinary management of this multidimensional condi-
tion (Robertson 2003; Rubenis 2007).
The physiotherapist is a member within this multidisciplinary
team (Robertson 2008; Rubenis 2007), whose purpose is to max-
imise functional ability and minimise secondary complications
through movement rehabilitation within a context of education
and support for the whole person (Plant 2000; Deane 2001a).
Physiotherapy for PD focuses on transfers, posture, upper limb
function, balance (and falls), gait, and physical capacity and
(in)activity by using cueing strategies, cognitive movement strate-
gies, and exercise to optimise the patient’s independence, safety,
andwell-being, thereby enhancing quality of life (Keus 2004; Keus
2007a).
Referral rates to physiotherapy for peoplewith PDhave historically
been low (Mutch 1986; Yarrow 1999). However, in recent years,
the number of referrals has increased, with a survey by Parkinson’s
UK in 2008 reporting that 54% of the 13,000 members surveyed
had seen a physiotherapist compared with 27% in a survey un-
dertaken in 1998 (PDS 2008; Yarrow 1999). This rise in referrals
may be attributed to two factors. First, guidelines published by
the National Collaborating Centre for Chronic Conditions (Nat
Collab Centre for Chronic Conditions 2006) recommended that
physiotherapy be made available throughout all stages of the dis-
ease, raising the profile of the profession. This has been further
supported by the publication of Dutch physiotherapy guidelines
(Keus 2004), which provide specific information for physiother-
apists involved in the management of PD. Second, a substantial
increase has been noted in the number of trials completed over the
past decade (particularly in the last five years), offering supportive
evidence for the inclusion of physiotherapy in the management of
PD (Keus 2009).
This Cochrane review assessing the effectiveness of physiother-
apy intervention versus no physiotherapy intervention in patients
with PD was first published in 2001, and included only 11 ran-
domised controlled trials with a total of 280 participants (Deane
2001a). Most of the trials in the review reported a positive effect
in favour of physiotherapy, but few outcome measures were statis-
tically significant. This, combined with the presence of method-
ological flaws, small sample sizes, and the possibility of publication
bias, led Deane et al. to conclude that evidence was insufficient
to support or refute the efficacy of physiotherapy for PD (Deane
2001a). This review updates the previous Cochrane review. We
appraised and synthesised relevant randomised controlled trials,
and we conducted a meta-analysis of outcomes where possible.
O B J E C T I V E S
To compare the effectiveness of physiotherapy intervention versus
no physiotherapy intervention in participants with PD.
To indirectly compare the different physiotherapy interventions
used within the various trials.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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For inclusion in the review, we considered all randomised con-
trolled trials (including the first phase of cross-over trials) compar-
ing a physiotherapy intervention with no physiotherapy interven-
tion (including placebo control). We included trials in which the
no intervention arm used an active or credible placebo, as long as
no physiotherapy was delivered to this group. We included only
trials that implemented random methods of treatment allocation.
Types of participants
Participants with a diagnosis of PD (as defined by the authors of
the studies):
• Any duration of PD.
• All ages.
• Any drug therapy.
• Any duration of physiotherapy treatment.
Types of interventions
Physiotherapy interventions aim to maximise functional ability
and minimise secondary complications through movement reha-
bilitation within a context of education and support for the whole
person. Physiotherapy encompasses a wide range of techniques, so
we were inclusive in our definition of physiotherapy interventions
(including those not delivered by a physiotherapist) with trials of
general physiotherapy, exercise, treadmill training, cueing, dance,
and martial arts included.
Types of outcome measures
Gait outcomes such as:
• Two- or six-minute walk test (m) measures the number
of metres a person can walk in two or six minutes, thereby
providing a measurement of walking endurance (Kersten 2004).
• Walking speed
◦ 10- or 20-metre walk test (s) measures the time in
seconds that a person takes to walk 10 or 20 metres, thereby
providing a measurement of gait speed (Kersten 2004).
◦ Speed (m/s) measures the rate of change of
position, recorded in metres per second (Trew 2005).
• Cadence (steps/min) measures the number of steps taken
in a given period, which is then converted into the number of
steps taken per minute (Trew 2005).
• Stride length (m) measures the average distance (in
metres) between two successive placements of the same foot
(Whittle 1996).
• Step length (m) measures the average distance (in
metres) between successive foot-to-floor contacts with opposite
feet (Trew 2005).
• Freezing of Gait Questionnaire validated questionnaire
for the assessment of freezing of gait. The questionnaire consists
of six items, and scores range from 0 to 24, with higher scores
corresponding to more severe freezing of gait (Giladi 2000).
Functional mobility and balance outcomes such as:
• Timed Up & Go (s) measures time taken in seconds for
a person to get up from a chair, walk a certain distance (usually
three metres), turn around, and walk back to the chair and sit
down (Podsiadlo 1991).
• Functional Reach Test (cm) “the maximal distance one
can reach forward beyond arm’s length, while maintaining a fixed
base of support in the standing position” (Duncan 1990).
• Berg Balance Scale validated questionnaire designed to
measure functional standing balance of the older adult. The
measure consists of 14 items, and scores range from 0 to 56, with
0 to 20 = high fall risk; 21 to 40 = medium fall risk; and 41 to 56
= low fall risk (Berg 1992; Qutubuddin 2005).
• Activity Specific Balance Confidence 16-item self-report
questionnaire that asks individuals to rate their confidence that
they will maintain their balance in the course of daily activities.
Each item is rated from 0% (no confidence) to 100% (complete
confidence) (Powell 1995; Talley 2008).
Data on falls such as:
• Number of patients falling e.g. falls diary.
• Falls Efficacy Scale 10-item patient-reported
questionnaire that measures how confident a person is at
carrying out various activities of daily living (ADL). Items are
rated from 1 to 10, with higher scores correlating with lower
levels of confidence, and a total score of 70 or higher indicating
that a person has a fear of falling (Tinetti 1990).
• Falls Efficacy Scale International 16-item questionnaire
that includes the 10 original items of the standard Falls Efficacy
Scale, as well as six items regarding higher functioning and social
activities. Each item is rated on a scale of 1 to 4, with 1 being
‘not concerned at all’ and 4 ‘very concerned’ (maximum score
out of 64) (Yardley 2005).
Clinician-rated impairment and disability measures such as:
• Hoehn & Yahr scale used to describe how symptoms of
Parkinson’s disease progress. Scale ranges from 0 to 5, with
higher levels indicating greater disability (Hoehn 1967).
• Unified Parkinson’s Disease Rating Scale (UPDRS)
designed to assess motor impairment and disability in
Parkinson’s disease. Higher scores correspond to greater disability
(Fahn 1987).
◦ Total scores range from 0 to 176.
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◦ Mental scores range from 0 to 16.
◦ ADL scores range from 0 to 52.
◦ Motor scores range from 0 to 108.
• Webster Rating Scale assessment of severity of disease
and clinical impairment against 10 items using a scale of 0=
normal to 3=maximum impairment: bradykinesia, rigidity,
posture, upper extremity swing, gait, tremor at rest, facial
expression, seborrhoea, speech, and self care. Scores range from 0
to 30, with higher scores indicating greater disease severity and
disability (Webster 1968).
• Columbia University Rating Scale assessment of motor
impairment and activities of daily living against 13 items, using a
five-point scale for each to yield a total score between 0=normal
and 65=maximum disability (Yahr 1969).
Patient-rated quality of life such as:
• Parkinson’s Disease Questionnaire39 (PDQ-39) PD-
specific health-related quality of life questionnaire containing 39
items divided among eight domains. Scores range from 0 to 100,
with higher scores corresponding to poorer quality of life
(Jenkinson 1997; Peto 1995).
• PDQUALIF PD-specific health-related quality of life
questionnaire containing 32 items in seven dimensions and one
item of global health-related quality of life. Total score ranges
from 0 to 128, with higher scores indicating poorer quality of life
(Welsh 2003).
• PDQL PD-specific health-related quality of life
questionnaire containing 37 items grouped into four subscales.
Item scores range from 1 to 5. The PDQL-Summary Index
ranges from 37 to 185, with higher scores reflecting better
quality of life (Deboer 1996).
• Short Form-36 or -12 generic short-form health survey
consisting of 36 or 12 questions. The SF-36 consists of eight
scaled scores assessing vitality, physical functioning, bodily pain,
general health perceptions, physical role functioning, emotional
role functioning, social role functioning, and mental health.
Scores range from 0 to 100, with higher scores corresponding to
better quality of life (Ware 1992).
Adverse events (e.g. fractures, pain).
Compliance (e.g. participant adherence, treatment fidelity).
Economic analysis.
Search methods for identification of studies
The review is based on the Movement Disorders Group search
strategy and the following more general search strategy:
• Physiotherapy OR physical therapy OR exercise OR
rehabilitation.
• Parkinson OR Parkinson’s disease OR Parkinsonism.
• #a AND #b.
Further details on this search strategy are available in the Group’s
module within The Cochrane Library (www.cochrane.org). This
includes explanations of the acronyms, sources, and Websites.
We undertook a systematic search of the literature up to the end
of January 2012 for publications or abstracts describing relevant
trials. This included searching:
• General biomedical and science electronic databases
(without date limiters) including the Movement Disorders
Review Group Specialized Register, The Cochrane Library,
MEDLINE (1966-2012), EMBASE (1974-2012), CINAHL
(1982-2012), and ISI-SCI (1981-2012); rehabilitation
databases: AMED (1985-2012), REHABDATA (1995-2012),
REHADAT, and GEROLIT (1979-2012); English language
databases of foreign language research and third world
publications: LILACS (1982-2012), MedCarib (17th Century-
2012), and IMEMR (1984-2012).
• The Cochrane Controlled Trials Register, the CentreWatch
Clinical Trials listing service, the metaRegister of Controlled
Trials, ClinicalTrials.gov, RePORT, PEDro, NIDRR, and NRR.
• Handsearching of general (Lancet, BMJ, JAMA) and
specific journals (Movement Disorders, Neurology, Archives of
Physical Medicine and Rehabilitation, Clinical Rehabilitation,
Physiotherapy, Physical Therapy) from 2001 to the end of January
2012.
• The reference lists of retrieved papers and review articles.
• Abstract books and conference proceedings. This included
The XIII International Congress on Parkinson’s Disease (1999),
The International Congress of Parkinson’s Disease and
Movement Disorders (1990, 92, 94, 96, 98, 2000, 02, 04, 05,
06, 07, 08, 09, 10, 11), World Congress on Parkinson’s Disease
and Related Disorders (2009, 2012), and The American
Academy of Neurology 51st Annual Meeting (1999).
• Grey literature databases (including theses): Conference
Proceedings Citation Index (1982-2010), DISSABS (1999-
2012), Conference Papers Index (1982-2012), Index to Theses
(1970-2012), Electronic Theses Online Service (EThOS) (16th
century-2012), and ProQuest dissertations and theses databases
(1861-2012).
Data collection and analysis
Selection of studies
Abstracts of potentially relevant studies from search results were
screened by two of the the four review authors involved in study
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selection (CT, SP, CH, LS). The full paper was obtained if the
abstract did not provide sufficient information for investigators
to determine eligibility for inclusion in the review. Disagreement
was resolved by referral to an additional review author (RS). We
contacted authors of potentially eligible studies for further infor-
mation if details of the trial were unclear.
Data extraction and management
Four review authors (CT, SP, CM, and CH) independently as-
sessed the identified papers and abstracts for trial details and out-
come data, and each eligible study was considered by two of these
four authors. This was validated by discussion, with any discrep-
ancies resolved by consensus. We recorded trial details on a stan-
dard trial description form and included the following: trial name,
trial group, authors, randomised comparison, treatment schedule
(including duration, number of sessions, type of intervention),
other therapy, eligibility criteria, method of randomisation, allo-
cation concealment, blinding, accrual period, number of partic-
ipants randomised, number of dropouts, duration of follow-up,
outcomes reported, use of intention-to-treat analysis, and publica-
tion date(s). Outcome data extracted included data on gait, func-
tional mobility and balance, falls, clinician-rated disability scale
and patient-rated quality of life, adverse events, compliance/with-
drawals, and health economics where available.
We contacted the authors of any eligible unpublished studies to ask
whether further details and data for their trial could be provided.
Assessment of risk of bias in included studies
We assessed the full papers for methodological quality by record-
ing eligibility criteria, methods of randomisation and blinding,
concealment of allocation, similarity of participants in treatment
groups at baseline, cointervention(s) constant, use of active or
credible placebo, whether an intention-to-treat analysis was per-
formed, and the numbers of participants lost to follow-up and
missing values (see Risk of Bias tables under Characteristics of in-
cluded studies).
Data synthesis
We combined the results of all trials using standard meta-analytic
methods to estimate an overall effect for physiotherapy interven-
tion versus no physiotherapy intervention.
All outcomeswith data available formeta-analysiswere continuous
variables, so we calculated the mean difference between treatment
arms using mean difference methods (Fleiss 1993). In summary,
this involved calculating for each trial the mean change (and stan-
dard deviation) from baseline to the postintervention time point
for the intervention and no intervention groups. From these, the
mean difference and its variance between arms for each trial could
be calculated. In some studies, the standard deviation for themean
change was not reported; in these cases, we imputed this stan-
dard deviation using the standard deviations for baseline and final
scores. To do this, we used the following formula to estimate the
variance of the change in score:
vardiff = varpre + varpost - 2r
√
(varpre varpost )
where vardiff is the variance of the change score; varpre is the vari-
ance of the baseline score; varpost is the variance of the final score;
and r is the correlation between pretreatment and post-treatment
scores. We assumed a correlation co-efficient of 0.5, which is a
conservative estimate, to reduce the chance of false-positive results
(Higgins 2011).
These values were then combined using weighted mean difference
methods to obtain the overall pooled estimate of the mean differ-
ence, with 95% confidence interval, for physiotherapy interven-
tion versus no physiotherapy intervention (control).
If any trials with three or more intervention arms were identified,
the following assumptions were made for the analysis:
• If the trial was comparing two or more physiotherapy
interventions within the same classification (see subgroup
analysis later) versus no intervention, then we combined the data
for these physiotherapy interventions to give one comparison of
physiotherapy intervention versus no intervention.
• If the trial was comparing two or more physiotherapy
interventions in different classifications versus no intervention,
then we included that trial in each relevant physiotherapy
intervention classification. This meant that some trials were
included multiple times in the analysis, and the control arms
from these trials were counted more than once in the analysis.
The primary analysis was a comparison of physiotherapy inter-
vention versus no physiotherapy intervention (control) based on
change from baseline to the first assessment after the treatment
period (which in most cases was immediately post intervention).
This was chosen as the primary analysis for this review, as in most
trials this was themain data analysis, and few trials reported data at
longer-term assessment points (i.e. after six months). Also, some
trials allowed participants in the ’no intervention’ arm to receive
physiotherapy intervention after this point. So this allowed a clean
comparison of physiotherapy intervention versus no physiother-
apy intervention.
Subgroup analysis and investigation of heterogeneity
The different trials implemented various types of physiotherapy
intervention. Therefore trials were divided according to the type
of intervention administered:
• General physiotherapy versus control.
• Exercise versus control.
• Treadmill versus control.
• Cueing versus control.
• Dance versus control.
• Martial arts versus control.
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To assess for differences between the different types of interven-
tions involved, we performed indirect comparisons using tests
of heterogeneity and I2 values to investigate whether the treat-
ment effect differed across the different interventions (Deeks2001;
Higgins 2003). The I2 value describes the percentage of variability
in effect estimates that is due to heterogeneity rather than to sam-
pling error (chance) (Higgins 2003). These tests may suggest the
possible superiority of one type of intervention over another, and
may provide clinicians and patients withmore reliable information
upon which to base decisions about therapy. However, as with all
subgroup comparisons, these analyses should be interpreted with
caution and should be considered hypothesis generating (Assmann
2000; Clarke 2001).
R E S U L T S
Description of studies
We identified 76 randomised trials of physiotherapy intervention
in PD patients. We excluded 31 studies (see Characteristics of
excluded studies). The reasons for excluding these trials were as
follows: cross-over study with data not presented for the first treat-
ment period or cross-over over a short period (e.g. 1 day) (n=6),
not randomised or not properly randomised (n=7), no outcome
measures relevant to our review (n=4), multidisciplinary therapy
rehabilitation trial (n=4), study was confounded (n=2) and treat-
ment given in trial was not usually used by physiotherapists (n=6),
excessive number of withdrawals (n=1), and insufficient informa-
tion (n=1). There were also six ongoing trials for which data were
not yet available (see Characteristics of ongoing studies). There-
fore, 39 trials were available for inclusion in the review compared
with 11 in the 2001 review (Figure 1).
7Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study PRISMA flow diagram.
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The number of participants randomly assigned into the 39 trials
ranged from six to 153 participants, with 1827 participants ran-
domly assigned in total (giving an average trial size of nearly 50
participants) (Characteristics of included studies). The assessment
period ranged from three weeks to 12 months. The mean age of
participants in the trials was 67 years, 64% were male, the mean
Hoehn & Yahr stage was 2.4, and participants had had PD for
approximately six years (Table 1).
One trial compared walking on a treadmill listening to music
versus walking on a treadmill without music versus listening to
music alone (Shankar 2009). We excluded the treadmill without
music arm of this trial from the analysis as this was a confounded
comparison.
Two three-arm trials compared two exercise interventions with
control. One compared exercise versus exercise and education ver-
sus control (Klassen 2007), and the other compared exercise versus
PD SAFEx versus control (Sage 2009a). The exercise interventions
being compared in these studies were considered suitably simi-
lar, so we combined the data from the two exercise arms within
each trial to obtain one comparison of exercise versus control. Two
three-arm trials compared two cueing interventions with control.
The overground and treadmill walking groups, each with equally
spaced transverse lines as cues, were combined to obtain a sin-
gle cueing versus control comparison (Almeida 2012). Finger tap-
ping and arm swing interventions were similarly combined (Haase
2011). One four-arm trial compared two types of dance (waltz/
foxtrot and tango) and martial arts with control. We combined
the two dance arms to obtain one comparison of dance versus con-
trol, as well as a martial arts versus control comparison (Hackney
2009).
Four other three-arm trials contributed data to two of the differ-
ent physiotherapy intervention comparisons. Two of these were
trials of cueing versus exercise versus control, which contributed
to both the cueing versus control and exercise versus control com-
parisons (Mak 2008; Thaut 1996). Another trial was of treadmill
versus general physiotherapy versus control, which contributed to
both the treadmill versus control and general physiotherapy versus
control comparisons (Fisher 2008). The last trial, which provided
no analysable data, contributed information to two comparisons:
general physiotherapy versus control and treadmill versus control
(Talakad 2011). The 39 trials therefore contributed data to 44
comparisons within the six different types of physiotherapy in-
terventions general physiotherapy versus control (n=7), exer-
cise versus control (n=14), treadmill versus control (n=8), cueing
versus control (n=9), dance versus control (n=2), and martial arts
versus control (n=4).
Below is a summary of the characteristics of included studies. De-
tails of individual studies are given in Characteristics of included
studies.
General Physiotherapy versus Control
The seven trials of general physiotherapy versus control in-
volved 244 participants (Chandler 1999; Ellis 2005; Fisher 2008;
Homann 1998; Keus 2007b; Stack 2012; Talakad 2011)). Sixty
participants split between physiotherapy and treadmill categories
are not included in this total as the group splits were not given
(Talakad 2011). The mean participant age was 65 years, 69%were
male, the mean Hoehn & Yahr stage was 2.4, and mean duration
of PD was four years. All trials were of parallel group design, ex-
cept one, which used a cross-over design (Ellis 2005). Treatment
sessions took place over a period of four weeks to 12 months;
duration of sessions was described by only two trials (Ellis 2005;
Stack 2012). One trial used Bobath training for gait and posture
(Homann 1998). The remaining trials provided multifaceted in-
terventions encompassing movement strategies, exercise, hands-
on techniques, education, and advice, targeting a wide range of
areas including gait, balance, transfers, posture, and physical fit-
ness. Thus, general physiotherapy is a holistic intervention and
on the whole uses a combination of techniques that do not rou-
tinely include complementary and/or alternative medicine such as
acupuncture or hypnotherapy.
Exercise versus Control
The 14 trials of exercise versus control involved 769 partici-
pants (Allen 2010; Ashburn 2007; Boehm 2011; Cerri 1994;
Goodwin 2009; Klassen 2007; Mak 2008; Meek 2010; Sage
2009a; Schenkman 1998; Schilling 2008; Stozek 2003; Taheri
2011; Thaut 1996). The mean participant age was 69 years, 60%
were male, the mean Hoehn & Yahr stage was 2.6, and mean du-
ration of PD was six years. Thirteen trials were of parallel group
design, and one used a cross-over design (Boehm 2011). Treat-
ment sessions lasted from 30minutes to two hours, and took place
over a period of three to 24 weeks. Exercise involved a variety
of different activities, including strengthening and balance train-
ing, walking, falls prevention, neuromuscular facilitation, resis-
tance exercise and aerobic training, and education and relaxation
techniques. Although sometimes multifaceted, the primary focus
of these interventions was exercise delivery, and treatment was fre-
quently categorised in this way by the trial authors.
Treadmill versus Control
The eight trials of treadmill versus control involved 179 partici-
pants (Cakit 2007; Canning 2008; Fisher 2008; Ganesan 2010;
Kurtais 2008; Protas 2005; Shankar 2009; Talakad 2011). Sixty
participants split between physiotherapy and treadmill categories
are not included in this total, as the group splits were not given
(Talakad 2011). The mean participant age was 68 years, 61%were
male, the mean Hoehn & Yahr stage was 2.4, and mean dura-
tion of PD was five years. All trials used a parallel group design.
Treatment sessions lasted from 30 to 60 minutes, and took place
over a period of four to eight weeks. Treadmill training mainly
9Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
involved participants walking on a treadmill with speed and/or in-
cline adjustments. Three trials used body weight-supported tread-
mill training (Fisher 2008;Ganesan 2010; Talakad 2011), and two
trials provided gait and step training (Kurtais 2008; Protas 2005).
Cueing versus Control
The nine trials of cueing versus control involved 371 participants
(Almeida 2012; de Bruin 2010a; de Bruin 2010b; Haase 2011;
Lehman2005;Mak 2008;Nieuwboer 2007; Shankar 2008;Thaut
1996). The mean participant age was 67 years, 59% were male,
the mean Hoehn & Yahr stage was 2.6, and mean duration of PD
was seven years. Eight of the trials were of parallel group design,
and one used a cross-over design (Nieuwboer 2007). Treatment
sessions lasted from four to 30minutes and tookplace over a period
of a single session to 13 weeks. Three types of cueing were used
in the trials: audio (music, spoken instructions), visual (computer
images), and sensory (vibration). Six trials applied external cues
during gait or gait-related activity, andMak (Mak 2008) used cues
for the rehabilitation of sit-to-stand transfers.
Dance versus Control
The two trials of dance versus control involved 120 participants
(Duncan 2012; Hackney 2009). The mean participant age was 69
years, 63% were male, the mean Hoehn& Yahr stage was 2.3, and
mean duration of PD was seven years. Both trials used a parallel
group design. Dance classes lasted one hour over 12 to 13 weeks,
with a trained instructor teaching participants the tango, waltz, or
foxtrot.
Martial Arts versus Control
The four trials of martial arts versus control involved 143 par-
ticipants (Hackney 2009; Marjama-Lyons 2002; Purchas 2007;
Schmitz-Hubsch 2006). The mean participant age was 65 years,
74% were male, the mean Hoehn& Yahr stage was 2.1, and mean
duration of PD was six years. All the trials were of parallel group
design, except one, which used a cross-over design (Purchas 2007).
Treatment lasted one hour and took place over a period of 12 to 24
weeks. Participants took classes on Tai Chi (three trials; Hackney
2009; Marjama-Lyons 2002; Purchas 2007) or Qigong (one trial;
Schmitz-Hubsch 2006).
Risk of bias in included studies
See: Characteristics of included studies, risk of bias in included
studies tables, risk of bias graph (Figure 2), and risk of bias sum-
mary (Figure 3).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Trial Design
Thirty-five trials had a parallel design and four had a cross-over de-
sign (Boehm 2011; Ellis 2005; Nieuwboer 2007; Purchas 2007).
The cross-over trials had no washout period, with participants as-
sessed at baseline, after the first treatment period, and then after
the second treatment period. Most trials looked at the short-term
effect of therapy by assessing participants at baseline and immedi-
ately or shortly after the physiotherapy intervention period (which
ranged from two to 52 weeks). Ten of the parallel design trials
(Almeida 2012; Ashburn 2007; Goodwin 2009; Klassen 2007;
Lehman 2005; Mak 2008; Meek 2010; Schmitz-Hubsch 2006;
Stack 2012; Stozek 2003) reported additional data at assessment
points after the treatment period had finished; this may have been
at only one week or up to 12 months after the end of the treatment
period.
Sample Size
Only six studies (15%; Allen 2010; Ashburn 2007; Duncan 2012;
Ellis 2005; Goodwin 2009; Nieuwboer 2007) reported a sample
size calculation in the trial report, three of which failed to achieve
their target (Ashburn 2007; Duncan 2012; Goodwin 2009).
Eligibility Criteria
Eligibility criteria for the trials were broad and varied consid-
erably across trials. The level of detail provided in the eligibil-
ity criteria was also variable, with some studies providing a de-
tailed description of the entry criteria, and others just stating “pa-
tients with Parkinson’s disease.” Only eight trials (Cakit 2007;
de Bruin 2010a; Homann 1998; Keus 2007b; Nieuwboer 2007;
Schmitz-Hubsch 2006; Shankar 2008; Stack 2012) stated that
a diagnosis of PD by the United Kingdom Brain Bank Criteria
(Gibb 1988) was required. It is vital that eligibility criteria are well
defined, so that the trial participant population can be determined.
Randomisation Method and Concealment of Allocation
Only 18 trials (46%) described the randomisation method used,
of which 11 trials used low-risk methods (e.g. block randomisa-
tion, computer random number generators). No details on the
randomisation method used were provided for the remaining 21
trials. Further, only 14 trials (36%) stated or gave adequate infor-
mation that allowed the assessment of whether an adequate con-
cealment of treatment allocation procedure had been used. Five
trials were considered to be low risk by virtue of the fact that they
used a central randomisation service, and the other nine were con-
sidered high risk (i.e. concealment of treatment allocation was po-
tentially compromised sealed envelopes, picking card or pick-
ing from a hat).
Blinding of Assessors
It would be impossible to blind participants and therapists to ran-
domised treatment allocation in trials of physiotherapy. Therefore,
such trials are open label by nature, and are consequently liable
to the possibility of both performance and attrition bias. How-
ever, assessors could be blinded to try to reduce the possibility of
bias. Twenty-four (62%) of the thirty-nine studies used blinded
assessors (although in one study, the assessors correctly guessed
the treatment allocation in nearly 30% of patients; unclear risk;
Ashburn 2007), three used unblinded assessors so were classed as
high risk, and in the other 12 studies, this information was not
provided (classed as unclear risk).
Description of the No Intervention (Control) Group
In most trials (n=34), the control group did not receive any phys-
iotherapy treatment or intervention; however, in five trials (Allen
2010; Ashburn 2007; Fisher 2008; Haase 2011; Shankar 2009),
an active placebo was used that attempted to control for the time
and attention involved in receiving physiotherapy intervention
compared with no treatment. This included contact with a PD
nurse, education classes, advice on falls prevention, and listening
to music. The control groups were followed-up and were assessed
in the same manner as the intervention groups.
Cointerventions
Information on cointerventions was provided in 23 trials (59%),
with participants continuing with their standard PD medication.
In 16 trials, this drug therapy was kept stable (low risk) through-
out the duration of the trial, whereas seven trials allowed variation
(unclear risk). The remaining 16 trials did not describe drug ther-
apy (unclear risk).
Similarity of Treatment Groups at Baseline
A description of the baseline characteristics of the trial participants
is important for determination of whether the trial results are
generalisable and for comparison of the characteristics of the two
arms to ensure that the randomisation methods were successful.
Six trials (de Bruin 2010b; Ganesan 2010; Homann 1998;
Marjama-Lyons 2002; Taheri 2011; Talakad 2011) did not pro-
vide any information on the baseline characteristics of partici-
pants entered into the trial. Twenty-eight (of the 33) trials that
reported baseline data gave this information split by treatment
group and showed participants to be similar at baseline. In ten tri-
als; the baseline characteristics of the withdrawn participants were
not given (Cakit 2007; de Bruin 2010a; Haase 2011; Hackney
2009; Klassen 2007; Kurtais 2008;Mak 2008; Purchas 2007; Sage
2009a; Schenkman 1998). This, along with the six studies that
did not supply baseline data, meant that 261 (14%) of the 1827
randomly assigned participants were not characterised.
Data Analysis
Nine trials stated intention-to-treat as the primarymethod of anal-
ysis, although it was not always clear if patients who withdrew
from the trial were included in the analysis. The number of patient
withdrawals was classed as low risk (≤ 10% of trial participants
withdrew) in seven of these nine trials. Three trials stated per pro-
tocol as the primary method of analysis. In the other 27 trials,
the method of analysis was not described (unclear risk). Of these
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trials, 12 were considered high risk in terms of the proportion of
patients that withdrew (i.e. > 10%), and in 14 trials, the number
of participant withdrawals (if any) was not given (unclear risk).
Data Available for Analysis
Thirteen trials were reported in abstract form. We requested fur-
ther information from authors; six (Boehm 2011; Haase 2011;
Klassen 2007; Meek 2010; Purchas 2007; Shankar 2008;) pro-
vided additional information, and seven (Cerri 1994; de Bruin
2010b; Ganesan 2010; Homann 1998; Marjama-Lyons 2002;
Shankar 2009; Talakad 2011) requests were unsuccessful. Suffi-
cient data were available for meta-analysis for five of the 13 studies
(Boehm 2011; Haase 2011; Klassen 2007; Meek 2010; Shankar
2009). Further, one trial had relevant data that could not be ex-
tracted as it was available only in graph form (Lehman 2005), and
another trial published only median and interquartile range data,
so their results could not be meta-analysed in this format (Stack
2012). Therefore data were not available for meta-analysis for ten
trials, meaning that of the 39 trials, data available for analysis were
provided by 29 trials.
Effects of interventions
Primary Analysis
Gait Outcomes
Two- or Six-Minute Walk Test (m)
Data on the two- or six-minute walk test were available from six
trials for seven comparisons within four physiotherapy interven-
tions (exercise, treadmill, dance, andmartial arts). (Note:Hackney
2009 contributed data to both the dance and martial arts compar-
isons.) Two hundred forty-two participants were included in this
analysis. A benefit of borderline significance was identified, along
with a greater increase in the distance walked in two or six minutes
with physiotherapy intervention compared with no intervention
(mean difference 13.37 m, 95% confidence interval (CI) 0.55 to
26.20; P = 0.04; see Figure 4). No evidence of heterogeneity was
found between the individual trials (P = 0.44, I2 = 0%), nor did
evidence suggest that the treatment effect differed across the four
physiotherapy interventions (P = 0.19, I2 = 37%).
Figure 4. 2- or 6-Minute walk test (m).Meek 2010 contributed to 2-minute walk test. Hackney 2009,
Schilling 2008, and Schenkman 1998 contributed to 6-minute walk test.
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10- or 20-Metre Walk Test(s)
Data on the 10- or 20-metre walk test were available from four
trials for two physiotherapy interventions (exercise and treadmill).
One hundred sixty-nine participants were included in the analysis.
Borderline significance was reported in favour of no intervention
for the time taken to walk 10 or 20 metres (0.40 s, CI 0.00 to
0.80; P = 0.05; see Figure 5). No evidence of heterogeneity be-
tween individual trials was obtained (P = 0.19, I2 = 38%), nor did
evidence indicate that the treatment effect differed across the two
physiotherapy interventions (P = 0.51, I2 = 0%).
Figure 5. 10- or 20-m walk test (s).Kurtais 2008 contributed to 20-m walk test. Meek 2010, Schenkman
1998, and Stozek 2003 contributed to 10-m walk test.
Speed (m/s)
Data on speed were available from 15 trials for 19 comparisons
within all six physiotherapy interventions. (Note: Fisher 2008;
Hackney 2009; Mak 2008; and Thaut 1996 all contributed data
to two physiotherapy comparisons.) Eight hundred fourteen par-
ticipants were included in this analysis. A significant benefit was
reported for physiotherapy, with speed increased by 4 cm/s with a
physiotherapy intervention compared with no intervention (0.04
m/s, CI 0.02 to 0.06; P = 0.0002; see Figure 6). No evidence
of heterogeneity was obtained between the individual trials (P =
0.55, I2 = 0%), nor any evidence of heterogeneity found between
the different types of physiotherapy intervention (P = 0.25, I2 =
25%).
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Figure 6. Speed (m/s).
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Cadence (steps/min)
Data on cadence were available from seven trials for nine com-
parisons within four physiotherapy interventions (general physio-
therapy, exercise, treadmill, and cueing). (Note: Fisher 2008 and
Thaut 1996 contributed data to two physiotherapy comparisons).
Three hundred fifty participants were included in this analysis. No
significant difference in cadence was observed between the two
treatment arms (-1.57 steps/min, CI -3.81 to 0.67; P = 0.17).
Stride Length (m)
Data on stride length were available from six trials for nine com-
parisons within all six physiotherapy interventions. (Note: Fisher
2008, Hackney 2009, and Thaut 1996 contributed data to two
physiotherapy comparisons.) Two hundred twenty-five partici-
pants were included in this analysis. No difference in stride length
was reported between the two treatment arms (0.03 m, 95% CI -
0.02 to 0.08; P = 0.24).
Step Length (m)
Data on step length were available from five trials for six com-
parisons within four physiotherapy interventions (general physio-
therapy, exercise, treadmill, and cueing). (Note: Fisher 2008 con-
tributed data to both the general physiotherapy and treadmill com-
parisons.) Three hundred eighty-three participants were included
in this analysis. No difference in step length was noted between
the two treatment arms (0.02 m, 95% CI 0.00 to 0.04; P = 0.06).
Freezing of Gait Questionnaire
Data from the Freezing of Gait Questionnaire were available from
four trials for three physiotherapy interventions (exercise, cueing,
and dance). Two hundred ninety-eight participants were included
in this analysis. A borderline significant benefit was noted, with
freezing of gait questionnaire score improved by 1.4 points with
a physiotherapy intervention compared with no intervention (-
1.41, 95% CI -2.63 to -0.19; P = 0.02, see Figure 7). No evidence
of heterogeneity between the individual trials was found (P = 0.74,
I2 = 0%), nor was there any evidence of heterogeneity between
the different types of physiotherapy interventions (P = 0.55, I2 =
0%).
Figure 7. Forest plot of comparison: 1 Gait Outcomes, outcome: 1.7 Freezing of Gait Questionnaire.
Functional Mobility and Balance Outcomes
Timed Up & Go (s)
Data on the Timed Up & Go test were available from nine tri-
als for ten comparisons within four physiotherapy interventions
(exercise, cueing, dance, and martial arts). (Note: Hackney 2009
contributed data to both the dance and martial arts comparisons.)
Six hundred thirty-nine participants were included in this analy-
sis. Overall, the time taken to complete the Timed Up & Go test
was significantly improved (i.e. reduced) with physiotherapy in-
tervention compared with no intervention (-0.63 s, 95% CI -1.05
to -0.21; P = 0.003; see Figure 8). No heterogeneity was observed
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between the individual trials (P = 0.12, I2 = 36%), nor between
the four physiotherapy interventions (P = 0.33, I2 = 12%).
Figure 8. Timed Up & Go (s).
The results for the Hackney et al. martial arts comparison were
heavily weighted in the analysis (48.8%) by very small standard
deviations (Hackney 2009) compared with the other studies. It
was also noted that in the trial publication, a nonsignificant (P =
0.093) effect of martial arts intervention was reported a find-
ing that contrasted with our data analysis, which reported a sig-
nificant improvement (P = 0.003). The author was contacted to
check whether the data reported in the paper were in fact stan-
dard errors, but they were confirmed as standard deviations. We
therefore performed a sensitivity analysis to remove this study and
found that the overall result became not significant (-0.38 s, 95%
CI -0.96 to 0.21; P = 0.21), so this result should be interpreted
with caution.
Functional Reach Test (cm)
Data on the Functional Reach Test were available from four trials
for two physiotherapy interventions (exercise and cueing). Three
hundred ninety-three participants were included in this analysis.
Functional reach was significantly improved with physiotherapy
intervention compared with no intervention (2.16 cm, 95% CI
0.89 to 3.43; P = 0.0008, see Figure 9). No evidence suggested
heterogeneity between the individual trials (P = 0.15, I2 = 44%),
nor did evidence indicate that the treatment effect differed across
the two physiotherapy interventions (P = 0.48, I2 = 0%).
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Figure 9. Functional Reach (cm).
Berg Balance Scale
Data on the Berg Balance Scale were available from five trials for
six comparisons within four physiotherapy interventions (exercise,
treadmill, dance, and martial arts). (Note: Hackney 2009 con-
tributed data to both the dance and martial arts comparisons.)
Three hundred eighty-five participants were included in this anal-
ysis. The Berg Balance Scale was significantly better after phys-
iotherapy intervention (3.71 points, 95% CI 2.30 to 5.11; P <
0.00001; see Figure 10). No evidence of heterogeneity between
the individual trials was noted (P = 0.06, I2 = 53%), nor did ev-
idence suggest that the treatment effect differed across the four
physiotherapy interventions (P = 0.47, I2 = 0%).
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Figure 10. Berg Balance Scale.
Activity-Specific Balance Confidence
Data on activity-specific balance confidence were available from
three trials for two physiotherapy interventions (exercise and cue-
ing). Sixty-six participants were included in this analysis. No dif-
ference between the two treatment arms was noted (2.40 points,
95% CI -2.78 to 7.57; P = 0.36).
Falls
Number of Falls
Seven trials (Ashburn 2007; Goodwin 2009; Marjama-Lyons
2002; Meek 2010; Nieuwboer 2007; Protas 2005; Purchas 2007)
attempted to record the number of falls during the trial period.This
was usually done by means of a falls diary, which can be difficult
to analyse and is subject to bias. Nevertheless, most of the individ-
ual trials reported a general trend for a reduction in the number
of falls with intervention. However, when compared with the no
intervention arm, this finding was not significant, except in one
trial. Marjama-Lyons 2002 reported a significant decrease in the
chance of fall frequency with Tai Chi intervention when compared
with no intervention.
Falls Efficacy Scale
Data on the Falls Efficacy Scale were available from four trials for
four comparisons within two physiotherapy interventions (exer-
cise and cueing). Three hundred fifty-three participants were in-
cluded in this analysis. No difference in the Falls Efficacy Scale
was found between the two treatment arms (-1.91 points, 95%
CI -4.76 to 0.94; P = 0.19).
Clinician-rated Disability
Only data on the Unified Parkinson’s Disease Rating Scale were
available for meta-analysis.
Unified Parkinson’s Disease Rating Scale (UPDRS)
Total
Data on the total UPDRS score were available from three trials for
four comparisons within three physiotherapy interventions (gen-
eral physiotherapy, exercise, and treadmill). (Note: Fisher 2008
contributed data to both the general physiotherapy and treadmill
comparisons.) Two hundred seven participants were included in
this analysis. Overall, the UPDRS total score was significantly im-
proved with physiotherapy intervention compared with no inter-
vention (-6.15 points, 95% CI -8.57 to -3.73; P =< 0.00001; see
Figure 11). Evidence of borderline heterogeneity was observed be-
tween the individual trials (P = 0.03, I2 = 67%), and between the
different types of physiotherapy intervention (P = 0.01, I2 = 77%).
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Figure 11. UPDRS total.
Mental
Data on the mental sub-scale of the UPDRS were available from
two trials for three comparisons within two physiotherapy in-
terventions (general physiotherapy and treadmill). (Note: Fisher
2008 contributed data to both the general physiotherapy and
treadmill comparisons.) One hundred five participants were in-
cluded in this analysis. No difference in UPDRS mental score was
reported between the two treatment arms (-0.44, 95% CI -0.98
to 0.09; P = 0.10).
Activities of Daily Living (ADL)
Data on the ADL sub-scale of the UPDRS were available from
three trials for four comparisons within three physiotherapy in-
terventions (general physiotherapy, treadmill, and dance). (Note:
Fisher 2008 contributed data to both the general physiotherapy
and treadmill comparisons.) One hundred fifty-seven participants
were included in this analysis. Overall, theUPDRS ADL score was
significantly improved with physiotherapy intervention compared
with no intervention (-1.36 points, 95% CI -2.41 to -0.30; P =
0.01; see Figure 12). No evidence of heterogeneity was observed
between the individual trials (P = 0.28, I2 = 22%), nor was there
any evidence of heterogeneity between the different types of phys-
iotherapy intervention (P = 0.19, I2 = 40%).
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Figure 12. UPDRS ADL.Earhart 2010, MDS-UPDRS.
Motor
Data on the motor sub-scale of the UPDRS were available from
12 trials for 14 comparisons within all six physiotherapy inter-
ventions. (Note: Fisher 2008 and Hackney 2009 contributed data
to two physiotherapy interventions.) Five hundred ninety-three
participants were included in this analysis. Overall, the UPDRS
motor score was significantly improved with physiotherapy inter-
vention compared with no intervention (-5.01 points, CI -6.30 to
-3.72; P < 0.00001; see Figure 13). Evidence indicated significant
heterogeneity between the individual trials (P = 0.0009, I2 = 63%)
and across the six physiotherapy interventions (P = 0.0001, I2 =
80%). A single outlying trial (Boehm 2011) was the source of this
heterogeneity, as upon exclusion of this trial from the analysis, the
result remained statistically significant (-3.77 points, 95% CI -
5.15 to -2.39; P < 0.00001), but the findings of tests for hetero-
geneity between trials (P = 0.44, I2 = 0%) and subgroups (P =
0.08, I2 = 50%) were no longer significant.
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Figure 13. UPDRS Motor.Earhart 2010, MDS-UPDRS.
Patient-rated Quality of Life
Only data on the Parkinson’s Disease Questionnaire-39 (PDQ-
39) for themobility domain and the summary index were available
for meta-analysis.
Parkinson’s Disease Questionnaire-39 (PDQ-39)
Summary Index
Data on the Summary Index of the PDQ-39 were available from
seven trials for eight comparisons within all six physiotherapy in-
terventions. (Note: Hackney 2009 contributed data to both the
dance and martial arts comparisons.) Four hundred five partici-
pants were included in this analysis. No difference between treat-
ment arms was observed in patient-rated quality of life after phys-
iotherapy intervention (-0.38 points, 95% CI -2.58 to 1.81; P =
0.73).
Mobility
Data on the mobility domain of the PDQ-39 were available from
two trials for three comparisons within three physiotherapy inter-
ventions (general physiotherapy, dance, and martial arts). (Note:
Hackney 2009 contributed data to both the dance and martial
arts comparisons.) One hundred five participants were included
in this analysis. No difference in the PDQ-39 mobility score was
observed between the two treatment arms (-1.43, 95% CI -8.03
to 5.18; P = 0.67).
Adverse Events
Notrials reported data on adverse events, and only one commented
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on adverse events, stating that none had occurred during treatment
sessions (Goodwin 2009).
Compliance
Only fourteen of the thirty-nine trials discussed patient compli-
ance, with twelve (Allen 2010; Canning 2008, Duncan 2012, Ellis
2005; Goodwin 2009, Keus 2007b; Klassen 2007; Kurtais 2008;
Meek 2010; Sage 2009a; Schenkman 1998; Schmitz-Hubsch
2006) quantifying it in some form; however, this was difficult to
analyse.
Health Economic
No trials reported data on health economic outcomes.
Subgroup Analysis
Only one outcome, the UPDRS motor sub-scale, showed signif-
icant heterogeneity between the treatment effects of the different
classes of interventions. In all other cases, no evidence of any dif-
ferences was found. However, one outlying trial was the cause of
this heterogeneity in the motor score (Boehm 2011); when this
trial was excluded from the analysis, the result remained significant
(−3.77 points, 95% CI -5.15 to -2.39; P < 0.001), but the test for
between-trial and between-subgroup heterogeneity was no longer
significant (P = 0.44 and P = 0.08, respectively).
D I S C U S S I O N
Summary of main results
This review updates the previous Cochrane review published in
2001 (Deane 2001a) comparing physiotherapy intervention ver-
sus no physiotherapy intervention for the treatment of PD. The
review now includes 39 randomised trials and 1827 participants
(compared with 11 trials and 280 participants in the 2001 review).
It also compares the different types of physiotherapy interven-
tions used in the treatment of PD, thus providing a comprehen-
sive assessment of physiotherapy treatment. Many recent system-
atic reviews have focused on specific areas of physiotherapy such
as exercise and cueing (Crizzle 2006; Goodwin 2008; Lim 2005;
Nieuwboer 2008). Nowadays, physiotherapy for PD encompasses
a wide range of methods and techniques ranging from standard
NHS physiotherapy to exercise regimens and martial arts. There-
fore, it is important that all forms of physiotherapy intervention
are included, so that the true benefit (if any) of physiotherapy can
be assessed. The review also includes a more comprehensive range
of outcome measures compared with previous reviews (18 out-
comes assessing gait, functional mobility and balance, falls, clin-
ician-rated Unified Parkinson’s Disease Rating Scale (UPDRS),
and patient-rated quality of life), thus providing the most reliable
summary available of the current published evidence.
Physiotherapy Intervention versus No Physiotherapy Inter-
vention
This review provides evidence of the short-term (< three months)
benefit of physiotherapy in the treatment of PD. All outcomes
showed improvement with physiotherapy intervention compared
with no intervention (except the 10- or 20-metre walk test). How-
ever, significant benefits after physiotherapy intervention were ob-
served only for the gait outcomes of speed, the two- or six-minute
walk test, and the Freezing of Gait questionnaire; the functional
and mobility outcomes of the Timed Up & Go test, Functional
Reach Test, and Berg Balance Scale; and the clinician-rated UP-
DRS. It is of interest that the direction of the treatment effect
favoured physiotherapy intervention in all outcome measures, ex-
cept one. The absence of evidence in these outcomes is not nec-
essarily evidence of the absence of benefit for physiotherapy. One
possible reason for this may be the lack of data. More than 1800
participants were randomly assigned into the 39 trials included
in this review, and 29 trials and 1577 participants (86% of total)
provided data for analysis. However, the greatest quantity of data
were provided for analysis of the outcome speed, and this included
just 15 trials and 814 participants (52% of the total number of
participants providing data). This general lack of extractable data
means that results of this meta-analysis should be interpreted with
caution.
Gait
People with PD frequently have problems with gait, and treatment
is usually targeted toward maximising exercise tolerance, improv-
ing the gait pattern, maintaining or increasing independence re-
garding mobility, and reducing the risk of falls. The most signif-
icant improvement among the outcomes assessing gait involved
speed. In light of previous experimental evidence, it may be hy-
pothesised that the improvement in speed is linked to an increase
in step or stride length, or both, and that this in turn leads to a
compensatory decrease in cadence (Morris 1994; Morris 1996).
In this review, although a significant improvement in speed was
observed, we found no difference in step length, stride length,
or cadence. This could again be due to lack of data, as a smaller
number of studies reported step and stride length and cadence (up
to seven studies) compared with speed (15 studies). Thus, further
data on the possible link between speed, cadence, step, and stride
length are required.
Freezing of gait is a prevalent motor disturbance within PD, and
it is known to have a detrimental impact on quality of life, as
well as on gait and mobility (Moore 2007). We found a border-
line significant difference in scores derived from the Freezing of
Gait Questionnaire, but this was measured in only four trials (298
participants), again highlighting the need for further data in this
important area.
Observed differences in the three significant gait outcomes (speed,
the two- or six-minute walk test, and freezing of gait) were rel-
atively small. Therefore, their relevance and benefit to patients
with PD must be put into context in terms of what is considered
a minimally clinically important change (MCIC). Speed was sig-
nificantly improved with physiotherapy intervention by 0.04 me-
tres/s. Data on what is considered an MCIC are lacking for PD
patients, but some data have been reported in stroke patients. In
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one study, it was reported that an increase in speed of just 0.03
and 0.13 metres/s could translate into a change from a limited
household to an unlimited household walker, and from an unlim-
ited household walker to a most-limited community walker, re-
spectively (Perry 1995). Our data are consistent with the findings
reported by Perry (Perry 1995). For the two- or six-minute walk
test and freezing of gait, participants who received physiotherapy
intervention were able to walk further over two or six minutes (by
13m) and their Freezing of Gait score was improved by 1.4 points.
Data on the MCIC are lacking for these outcomes, but although
a 13-m increase in distance walked would probably be considered
clinically important, the importance of a 1.4-point improvement
in freezing of gait is less clear.
Functional Mobility and Balance
Changes in functional mobility and balance within PD have been
well documented (Bloem 2001). Of the functional mobility and
balance outcomes assessed within this review, significant improve-
mentswere observed in theTimedUp&Go test, Functional Reach
Test, and Berg Balance Scale. The time taken to complete the
Timed Up & Go test was significantly improved by 0.63 seconds
with physiotherapy. Despite this significant change, the MCIC in
PD patients is thought to be 11 seconds (Steffen 2008). Therefore,
the small change observed within this review may not translate
into a noticeable improvement in a person’s functional mobility.
A five-point change is theMCICon theBergBalance Scale (Steffen
2008). In this review, a significant four-point improvement in the
Berg Balance Scale was noted after physiotherapy intervention. A
greater evidence base is required to support or refute the clinical
significance of this result. A significant improvement of 2 cm was
also noted in the Functional ReachTest, but this is somewhat lower
than the MCIC of 9 cm and 7 cm for the forward and backward
Functional Reach Test (Steffen 2008).
Falls
Falls are a common and disabling problem within PD (Bloem
2001), with high clinical impact and serious cost implications to
society. They are also a recurrent problem, with up to 51% of
those falling reporting two or more falls per year (Wood 2002).
Fear of falling has been recognised as a contributing factor to re-
current falls (Mak 2009). Within this review, fear of falling has
been captured through the Falls Efficacy Scale (standard and in-
ternational). No difference between treatment arms was observed
for this outcome. This might be attributed to the small number of
trials (and therefore participants) included within these analyses,
but could also indicate that an improvement in balance does not
automatically result in increased confidence in an individual’s abil-
ity not to fall. In turn, it could be hypothesised that improvement
in balance does not directly equate to improved levels of mobility
and independence. Although fear of falling was not reduced with
physiotherapy within this review, it would be of interest to assess
whether the number of falls was reduced, as this may be more rele-
vant to patients. Unfortunately, data on this were poorly reported
and were measured too variably within the trials; therefore, they
could not be meta-analysed. However, in the seven trials in which
data on the number of falls were reported, a general trend toward a
reduction in the number of falls with physiotherapy intervention
was seen, but with no difference between the two treatment arms.
Clinician-Rated Disability
Significant improvements after physiotherapy intervention were
also observed for the clinician-rated UPDRS (total, ADL, andmo-
tor scores). The UPDRS total score was improved by 6.2 points,
the ADL score by 1.4 points, and motor score by 5.0 points. The
MCIC for the UPDRS have been reported in two studies. One
analysed data from two independent randomised controlled trials
and concluded the MCIC to be eight points for the UPDRS to-
tal score, between two and three points for the ADL score, and
five points for the motor score (Schrag 2006). The second study
performed a cross-sectional analysis on 653 PD participants, and
reported MCIC of 2.3 to 2.7 points for motor and 4.1 to 4.5
points for total UPDRS (Shulman 2010). If the recommendations
of both Schrag (Schrag 2006) and Shulman et al (Shulman 2010)
are taken into account, it can be concluded that the significant
improvements observed within this review are approaching or are
MCICs (theMCICs for theUPDRS total, ADL, andmotor scores
lie within the confidence interval). This suggests that physiother-
apy intervention is beneficial in improving motor symptoms and
may positively impact ADL.
Patient-Rated Quality of Life
No significant benefit of physiotherapy intervention for overall
patient-rated quality of life (measured using the Parkinson’s Dis-
ease Questionnaire (PDQ)-39 Summary Index) or the mobility
domain of the PDQ-39 was noted, which is surprising in light
of the significant improvements seen in UPDRS scores. Another
study (Chandler 1999) assessed patient quality of life using the
generic Short Form-36 and also showed no effect of physiotherapy
intervention.
Comparison of Different Physiotherapy Interventions
Although we found short-term benefit for physiotherapy inter-
vention in the treatment of PD, what is less clear is whether a
certain type of physiotherapy intervention may provide greater
benefit. This information would be of interest to both clinicians
and patients, so that appropriate physiotherapy interventions that
provide greater benefit can be delivered to patients with PD. To
assess this, we categorised the various physiotherapy interventions
used in the trials included in this review according to the type of
treatment administered, and then compared them using tests for
heterogeneity.We found no real evidence of any differences in the
treatment effect between the different physiotherapy interventions
used for any of the outcomes assessed. However, these were based
on indirect comparisons (with limited data within each physio-
therapy intervention) so should be interpreted with caution. They
would be better assessed in trials directly comparing different types
of physiotherapy interventions.
This lack of difference between the different types of physiother-
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apy intervention is perhaps not surprising. The content and de-
livery of the interventions used in the trials included within this
review are diverse in nature and, although attempts were made
to compare trials ’like for like’ through the creation of different
categories, the interventions delivered varied substantially within
these categories. The variety in the therapies delivered is perhaps
not surprising. By nature physiotherapists are autonomous pro-
fessionals with differing sets of skills who work within their own
scope of practice (Chartered Society of Physiotherapy), and so this
variation in the interventions delivered within clinical trials may
actually reflect clinical practice. Second, and perhaps more impor-
tant, PD is recognised as a complex condition with an individu-
alised presentation (van der Marck 2009). For this reason, Morris
et al (Morris 2010) recognises the importance of the physiothera-
pist’s understanding the specific experience of PD in each patient,
and advocates that treatment is tailored to fit the individual’s com-
plaints, lifestyle, and personal interests, as opposed to a ’one size
fits all’ approach. Over the past decade, steps have been taken to
try to provide best practice consensus in the form of the Dutch
KNGF guidelines for physical therapy in patients with Parkinson’s
disease (Keus 2004). However, this publication provides a guid-
ance framework rather than a ’recipe’ for treatment. It is therefore
important that physiotherapy interventions are compared against
each other within rigorous trial designs to determine which are
most effective. This will provide therapists with a menu of treat-
ment strategies that are known to be effective, from which they
can devise individualised interventions.
Quality of the evidence
Improvement in trial methodological quality and reporting has
been noted since the last Cochrane review (Deane 2001a). The use
of more robust randomisation methods, blinding, and intention-
to-treat analyses had increased since the previous review but was
still inadequate. Only 18 of the 39 trials provided information
on the randomisation method (of which eleven were considered
low risk), and only five used a central randomisation procedure
to ensure concealment of treatment allocation. Twenty-four used
blinded assessors and nine reported using intention-to-treat anal-
ysis. The lack of information on this in many trial reports may not
necessarily indicate lack of implementation within the trial, but
without this information, the level of bias within the individual
trials is difficult to assess. This does, therefore, reduce the amount
of confidence that can be placed in the results of this meta-analysis.
The need for further improvement in the methodological quality
of trials in physiotherapy for PD was noted in another recent sys-
tematic review (Kwakkel 2007). Future trials need to ensure that
their designs fulfil the requirements of a methodologically sound,
large, randomised controlled trial, and that the reporting follows
the CONSORT guidelines (Schulz 2010).
The trials included in the review were relatively small, with most
assessing the effects of physiotherapy intervention versus no phys-
iotherapy intervention over a short period with limited follow-
up. The overall size of trials has increased (with an average of 46
participants per trial in this review compared with 25 in the pre-
vious review), but the number of small and underpowered trials
remains a problem. Small trials may be subject to ‘random error’
(Doll 1980), and consequently may give rise to false-negative or -
positive results. To highlight this point, this review illustrates that
any differences observed in the various outcome measures show-
ing benefit for physiotherapy were quite small. So trials need to be
large enough to detect these small but possibly clinically impor-
tant differences.
Further, it must be noted that only 14 of the 39 trials discussed
participant compliance. This is surprising in that compliance can
be an important determinant of the outcomes measured in trials.
Therefore, it would be beneficial if the level of compliance is mea-
sured in future trials.
Another limitation is that the follow-up period in the trials in-
cluded in this review was relatively short. Outcomemeasures were
assessed by all trials at baseline and immediately or shortly after in-
tervention had ceased (one or two weeks with one trial (Goodwin
2009) assessing at 10 weeks post intervention). Thus, this review
is able to provide conclusions only on the short-term benefits of
physiotherapy. It is also important to consider results alongside
the possibility of a so-called honeymoon effect (Goetz 2008) in
the period during or just after physiotherapy, which may inflate
the treatment effect in favour of physiotherapy. Parkinson’s dis-
ease is a long-term neurodegenerative disease, so it is important
that the long-term effect of treatment be assessed. Only 12 of
the 39 trials followed-up participants and reported further data
during the post-treatment period (but this could have been only
one week or up to six months post the treatment period). The
recommendations of the previous review were that participants
should be followed-up for at least six months, but only one trial
(Schmitz-Hubsch 2006) reported follow-up data at six months
post treatment completion. Long-term data will provide valuable
information about the duration of any improvement following
therapy.
The outcome measures included in this review are standard phys-
iotherapy and PD outcomes. However, PD is a multidimensional
disease, and many important outcomes were poorly reported or
were not reported, this includes data on the number of falls, de-
pression and anxiety, adverse events, and the health of the caregiver
supporting the person with PD. Further, no health economics
analysis of physiotherapy intervention was reported; therefore lit-
tle is known about the cost-effectiveness and economic value of
this therapy. Future trials should include these outcomes.
In summary, this review provides evidence of the short-term (<
three months) benefit of physiotherapy intervention for the treat-
ment of PD. It is important to note that although most of the ob-
served differences between the two treatments were small, the im-
provements observed for speed, Berg Balance Scale, and UPDRS
scores were at levels considered to be of clinical importance. To
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clarify the long-term (if any) benefit of physiotherapy, additional
large, well-designed randomised trials with a follow-up of at least
12 months, alongside a health economics assessment, are needed
to assess the impact of this treatment on all aspects of a patient’s
PD.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Physiotherapy provides short-term benefit in the treatment of
PD. Significant benefits with physiotherapy intervention were ob-
served for the following outcomes: two- or six-minute walk test,
speed, Freezing of Gait questionnaire, TimedUp&Go test, Func-
tional Reach Test, Berg Balance Scale, and UPDRS total, ADL,
and motor scores. Although most of the observed differences be-
tween the two treatment arms were small, the improvements seen
for speed, Berg Balance Scale, and UPDRS scores occurred at lev-
els that may be considered to be of clinical importance. These
benefits should be interpreted with caution, however, because the
quality of most of the included trials was not high.
The long-term, if any, benefit of physiotherapy remains unidenti-
fied, as does which type of physiotherapy intervention should be
delivered. Therefore, although this review has provided evidence
that physiotherapy intervention may be of benefit to PD patients,
it has also highlighted that further evidence is needed before firm
conclusions can be made on the long-term benefit and on which
physiotherapy intervention should be used.
Implications for research
Most of the studies in this review were small and had a short fol-
low-up period. It is clear that larger randomised controlled trials
are required, particularly focusing on improving trial methodol-
ogy and reporting. Rigorous methods of randomisation should be
used and the allocation adequately concealed.Data should be anal-
ysed according to intention-to-treat principles, and trials should
be reported according to the guidelines set out in the CONSORT
statement (Schulz 2010).
A large variety of outcome measures were assessed in these trials,
but data were sufficient only for meta-analysis to be performed for
eighteen outcomes. This variation in outcome selection and lack
of extractable data resulted in a small proportion of included trials
contributing to each outcome. This review illustrates the need for
the universal employment of relevant, reliable, and sensitive out-
come measures. Additionally, only one trial looked at the longer-
term benefit of physiotherapy intervention. To assess whether, or
how long, any improvements due to physiotherapy intervention
may last, it is important that long-term follow-up is performed.
No evidence indicates the best form of physiotherapy interven-
tion. Comparisons of the different physiotherapy interventions
described in this review were based on indirect comparisons be-
tween individual trials. A more reliable comparison would be ob-
tained in large, randomised trials that directly compare different
physiotherapy interventions.
This review highlights the variety of physiotherapy interventions
being used in the treatment of PD. More specific trials with im-
proved treatment strategies are needed to underpin the most ap-
propriate choice of physiotherapy intervention and the outcomes
measured.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Allen 2010
Methods Parallel group design.
Randomised using a randomisation schedule with randomly permuted block sizes, developed by an
investigator not involved in subject recruitment or assessment
Data analysed on an intention-to-treat basis.
Treated as outpatients and at home for 48-72 hours over 6 months
Assessed at baseline and post intervention.
Assessors were blinded.
Participants 24 participants in the exercise group and 24 in the control group. 3 drop-outs in the exercise group
Participants’ mean age was 66 years (exercise) and 68 years (control); male/female 13/11 (exercise) and
13/11 (control); duration of PD 7 years (exercise) and 9 years (control). Hoehn and Yahr stage not
reported
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease, able to walk independently (with or
without an aid), fallen in the last year or deemed to be at risk of falling, 30-80 years of age, and on the
same PD medication for the past 2 weeks. Exclusion criteria: significant cognitive impairment (Mini
Mental State Examination [MMSE] <24), had another neurological/musculoskeletal/cardiopulmonary/
metabolic condition that would interfere with safe conduct of the training or testing protocol
Interventions Exercise: 40- to 60-minute program of progressive lower limb strengthening and balance exercises
(targeted legmuscle strength, balance, and freezing). Once-monthly exercise classes, with the remaining
exercise sessions at home
Control: usual care with advice on fall prevention and falls diary recording any fall
Drug therapy was allowed to vary.
Outcomes PD falls risk score.
Knee extensor strength.
Coordinated stability.
Sway.
Maximum balance range in standing.
Alternate step test.
Freezing of Gait Questionnaire.
Sit-to-stand time.
Fast walking speed.
Comfortable walking speed.
Short physical performance battery.
Falls Efficacy Scale International.
PDQ-39.
Participants were assessed in their home about 1 hour after taking their usual PD medication, and the
order of measurements was standardised
Notes Participants in the exercise group who experienced freezing of gait were also instructed in cueing
strategies to reduce freezing as part of their exercise program
Exercise group completed a mean of 70% of total prescribed exercise sessions
Risk of bias
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Allen 2010 (Continued)
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Randomly permuted block size.
Concealment of Allocation Unclear risk No information provided.
Similarity at Baseline Low risk
Withdrawals Described Low risk 6% overall, but all from exercise group.
Intention To Treat Analysis Low risk An intention-to-treat approach was used for all
analyses.
Cointerventions Constant Unclear risk Allowed variation in levodopa therapy.
Credible Placebo Low risk Falls prevention advice given in both arms.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Almeida 2012
Methods Parallel group design.
Randomised by pulling allocation out of a hat.
Analysed on a per protocol basis.
Treated as outpatients for 9 hours over 6 weeks.
Assessed at baseline, 6 weeks, and 12 weeks.
Assessors were blinded for UPDRS III evaluation.
Participants 14 participants in the Overground walking group (OG), 14 in the Treadmill walking group (TM), and
14 in the control group (CL). 2 dropouts in TM group, 1 dropout in CL group
Participants’ mean age 73.9 years (OG), 63.9 years (TM), and 67.4 years (CL); male/female 12/2 (OG)
, 8/6 (TM), and 11/3 (CL); Hoehn and Yahr stage not stated; duration of PD not stated
Inclusion criteria: confirmed as having clinically typical Parkinson’s disease by at least one movement
disorders neurologist. Exclusion criteria: past history of neurological conditions other than Parkinson’s
disease, orthopaedic or visual disturbances that severely impaired walking ability, unable to indepen-
dently walk down an 8-meter GAITRite carpet for a total of 10 trials
Interventions OG: walk down equally spaced transverse lines presented on a 16-m carpet. The cues were white lines
of tape. Participants asked to walk across the lines, turn, and continue back. Spacings were set at 8%
greater than the initial step length of any of the groups (70 cm). 30-Minute session with mandatory 2-
minute break every 8 minutes, additional rest allowed if necessary, but a total of 24 minutes of walking
was required for a gait session to be considered complete
TM:Walk on a treadmill presentedwith equally distributed standardised transversewhite lines. Spacings
were set at 8% greater than the initial step length of any of the groups (70 cm). 30-minute session
with mandatory 2-minute break every 8 minutes, additional rest allowed if necessary, but a total of 24
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Almeida 2012 (Continued)
minutes of walking was required for this gait session to be considered complete
CL: instructed to continue their usual activities.
Participants were optimally medicated at time of all training and testing sessions and remained on
stable regimen throughout trial period
Outcomes Step length.
UPDRS III.
Timed up and go.
Gait speed.
Cadence.
Double support time.
Step time.
Step-to-step variability, Step time variability.
30-Ssecond chair stand.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria stated.
Randomisation Method High risk Allocation pulled out of hat.
Concealment of Allocation High risk Allocation pulled out of hat.
Similarity at Baseline Low risk
Withdrawals Described Low risk Withdrawals at less than 10%.
Intention To Treat Analysis High risk Analysed on a per protocol basis.
Cointerventions Constant Low risk Participants maintained stable drug regiment
throughout trial period
Blinded Assessors Low risk Assessors blind for UPDRS III evaluation only.
(This is the only subjective outcome.)
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Ashburn 2007
Methods Parallel group design.
Stratified by NHS using blocks of size four. Random allocation by telephoning the medical statistics
group at University of Southampton. Participants were informed of their allocation by telephone
Data analysed on an intention-to-treat basis.
Treated as outpatients 7 times a week for a 6-week period, for a total period of 42 hours
Assessed at baseline, 8 weeks, and 6 months.
Participants 70 participants in the exercise group and 72 in the control group. 6 dropouts in the exercise group and
8 in the control group
Participants’ mean age 72.7 years (exercise), 71.6 years (control); male/female 38/32 (exercise), 48/24
(control); Hoehn and Yahr stage 3.14 (exercise), 3.11 (control); duration of PD 7.7 years (exercise), 9
years (control)
Inclusion criteria: confirmed diagnosis of Parkinson’s disease, independently mobile, living at home
in the community, experienced more than one fall in the previous 12 months, passed a screening for
gross cognitive impairment (Mini-Mental State). Exclusion criteria: unable to participate in assessments
because of pain, acute medical condition, in receipt of or soon to receive treatment
Interventions Exercise: personalised home-based exercise and strategy programme. After assessment, treatment goals
were established with participants, and exercises from the exercise menu were taught. Participants were
visited weekly at home by a physiotherapist for approximately 1 hour. 6 levels of exercise progression
comprised muscle strengthening, range of movement, balance training, and walking. Strategies of falls
prevention and movement initiation and compensation taught by physiotherapist. Participants were
asked to complete the exercises daily for max of 1 hour and to keep a record. Phoned monthly to
encourage exercises
Control: usual care, contact with local Parkinson’s disease nurse
Drug therapy was not described.
Outcomes Self-reported falls diary.
Functional reach.
Timed up and go test.
Chair stand test.
Berg balance test.
Euroqol-5d, QoL thermometer.
Self-assessment Parkinson’s disease disability scale.
Tests were carried out midway between drug doses.
Notes At 6 months, 34% in the control group were participating in extra rehabilitation compared with 25%
in the exercise group
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Block randomisation (block size 4).
Concealment of Allocation Low risk Telephone call to central office.
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Ashburn 2007 (Continued)
Similarity at Baseline Low risk
Withdrawals Described Low risk 6% at 8 weeks and 8% at 6 months.
Intention To Treat Analysis Low risk Analysis was on an intention-to-treat basis.
Cointerventions Constant Unclear risk Drug therapy was not described.
Credible Placebo Low risk Controls had contact with Parkinson’s disease
nurse.
Blinded Assessors Unclear risk Assessor remained blind to group allocation but
reported being aware of the allocation of 18 exer-
cise and 11 control participants at 8 weeks, and 25
exercise and 14 control participants at 6 months
Boehm 2011
Methods Cross-over design.
Random allocation generated and implemented by trial coordinator
Analysed on a per protocol basis.
Treated for 12 weeks.
Assessed at baseline, 12 weeks, and 24 weeks.
Assessors were blinded for UPDRS III evaluation.
Participants 55 participants in sensory attention focused exercise group (SAFE) and 55 in control group . 5 dropouts
in SAFE group, 3 dropouts in control group
Participants’ mean age 67.4 years (SAFE), 65.8 years (control); male/female 28/22 (SAFE), 30/22
(control); Hoehn and Yahr stage not stated; duration of PD 5.4 years (SAFE), 5.2 years (control)
Inclusion criteria: idiopathic Parkinson’s disease diagnosed by neurologist or movement disorders spe-
cialist according to international clinical diagnosis criteria, able to commit to study guidelines for 24
weeks. Exclusion criteria: score lower than 76 on 3MS (extended MMSE)
Interventions Sensory attention focused exercise.
Control: no intervention.
Drug therapy was not described.
Outcomes UPDRS I, II, & III.
Timed up and go.
Step length.
Step length variability.
Gait speed.
Grooved peg-board.
30 second chair stand.
Notes Abstract and unpublished data. Baseline characteristics do not include dropouts
Risk of bias
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Boehm 2011 (Continued)
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria stated.
Randomisation Method Unclear risk Randomisation method not clear.
Concealment of Allocation Unclear risk Randomisation method not clear.
Similarity at Baseline Low risk
Withdrawals Described Low risk Withdrawals at 7%.
Intention To Treat Analysis Low risk Analysed on a per protocol basis.
Cointerventions Constant Low risk Drug therapy constant.
Blinded Assessors Low risk Assessors were blinded for UPDRS III evaluation.
Cakit 2007
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for an unspecified time over 8 weeks (30-minute sessions)
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 27 participants in the treadmill group and 27 in the control group. 6 dropouts in the treadmill group,
17 dropouts in the control group
No baseline characteristics given for dropouts. Participants’ mean age 71.8 years; male/female 16/15.
The Hoehn and Yahr scores were not given. The mean duration of PD was 5.6 years
Inclusion criteria: Parkinson’s disease patients who fulfilled the UK Parkinson’s Disease Society Brain
BankCriteria, weremedically stable, were able towalk 10-metre distance at least 3 timeswith or without
assistive device, able to provide informed consent. Exclusion criteria: participants who had neurological
conditions other than idiopathic Parkinson’s disease, scored greater than 3 in Hoehn and Yahr, scored
less than 20 in MMSE, postural hypotension, cardiovascular disorders, class C or D exercise risk by the
American College of Sports Medicine (ACSM) criteria, musculoskeletal disorders, visual disturbance
or vestibular dysfunction limiting locomotion or balance
Interventions Treadmill: 8-Week exercise programusing incremental speed-dependent treadmill training. Programme
comprised stretching, range of motion exercise, and treadmill training. The treadmill session lasted
for 30 minutes and participants were observed during treadmill training by a physiatrist, who gave
no assistance in the actual performance of the movements. Maximum tolerated walking speed was
determined before the training session began. This speed then was halved and was used for a 5-minute
warm-up period. After the warm-up period, the belt speed was increased by increments of 0.6 km/h
every 5 minutes. When the belt speed was increased to the highest speed at which the participant could
walk safely and without stumbling, this maximum-achieved belt speed was maintained for 5 minutes
and then was followed by 0.6-km/h decrements. The participant maintained the rest of the treadmill
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Cakit 2007 (Continued)
session at this speed for 15 minutes
Control: no intervention.
Drug therapy was constant during the trial.
Outcomes Berg Balance Test.
Dynamic Gait Index.
Falls Efficacy Scale.
Walking distance on treadmill.
Tolerated maximum speed on treadmill (km/h).
Examinations took place when participants were in the ’on’ phase of medication
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
Similarity at Baseline Unclear risk Baseline data given overall, not split by treatment
group.
Withdrawals Described High risk 43% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drug therapy was constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Canning 2008
Methods Parallel group design.
Randomised using opaque envelopes pre-prepared by an investigator and randomly allocated by staff
member not involved in the trial
Data analysed on an intention-to-treat basis..
Treated at home 4 times a week for 6 weeks, for a total of 12 to 16 hours
Assessed at baseline, 6 and 12 weeks.
Assessors were blinded.
Participants 10 participants in the treadmill group and 10 participants in the control group. Dropouts 2 (treadmill)
, 1 (control)
Participants’ mean age 60.7 years (treadmill), 62.9 years (control); male/female 5/5 (treadmill), 6/4
(control); Hoehn and Yahr stage not stated; duration of PD 6.1 years (treadmill), 5.2 years (control)
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Canning 2008 (Continued)
Inclusion criteria: clinical diagnosis of idiopathic Parkinson’s disease, aged 30 to 80 years, able to walk
unaided but with subjective disturbance of gait and/or a Unified Parkinson’s Disease Rating Scale
(UPDRS) gait sub score of 1 or 2, sedentary, defined as performing less than 2 hours/week of leisure-
time physical activity over the prior 3 months, have adapted to current anti-Parkinsonian medication
for at least 2 weeks, is cognitively intact, has no freezing ’on’ medication, Hoehn and Yahr stage 1 or 2.
Exclusion criteria: motor fluctuations or dyskinesias that are disabling, requiring the use of a walking
aid; more than one fall in the past 12 months, Mini-Mental State Examination score < 24, exhibit other
neurological or musculoskeletal conditions affecting walking, chest pain at rest or during exercise in
the past 3 months, or heart attack, angioplasty, or heart surgery in the last 6 months
Interventions Treadmill: 30- to 40-minutes sessions included 5-minute warm up and cool down, sit-to-stand exercise
and stretch exercises followed by treadmill walking. The intensity of training progressed over 6 weeks.
Cognitive and manual tasks introduced during walking from week 4. Verbal and visual cues also
provided for encouragement. 7 sessionswere supervised in the home by a physiotherapist. Other sessions
were completed independently
Control: advised to maintain current activity levels.
17 participants taking LD ranging from 100 to 1200 mg. 10 were also being treated with DA and 2
were also taking COMTI. Three (2 control and 1 experimental) were taking no PD medication
Outcomes 6-Minute walk test.
UPDRS motor examination.
PDQ-39.
Walking automaticity, speed of walking 10 m while performing a concurrent (cognitive or cognitive +
physical) task, as expressed as a percentage of the walking speed of walking 10 m without performing
the concurrent task
Walking consistency determined as the coefficient of variation for stride time and stride length recorded
during the 6-minute walk test
7-pt Likert scale to assess fatigue.
Examinations took place during ’on’ periods.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Randomised using opaque envelopes pre-prepared
by an investigator
Concealment of Allocation High risk Randomly allocated by staff member not involved
in the trial
Similarity at Baseline Low risk
Withdrawals Described Low risk 10% dropout/withdrawal rate at 6 weeks (primary
endpoint). Increases to 15% dropout/withdrawal
rate by 12 weeks
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Canning 2008 (Continued)
Intention To Treat Analysis Low risk Data analysed on an intention-to-treat basis.
Cointerventions Constant Unclear risk Not stated whether any changes to medications
occurred during trial period
Blinded Assessors Low risk Assessors were blinded to group allocation.
Cerri 1994
Methods Parallel group design.
Randomisation method was not stated.
Method of analysis not described.
Treated as outpatients for 15 hours over 3 weeks followed by a home exercise program for 2 months,
then the cycle was repeated. (Total of 30 hours therapy.)
Assessed at baseline and immediately after treatment.
Not stated whether assessors were blinded.
Participants 3 participants in the exercise group and 3 in the control group. Dropouts not described
Participants’ were all aged between 58 and 68 years at Hoehn and Yahr stage 3 and 4. No data given
for the sex of the participants
Inclusion criteria: Parkinson’s disease, stage 3 and 4 of Hoehn and Yahr scale, treated with L-dopa for
longer than 4 years with incomplete control of rigidity and tremor. No exclusion criteria stated
Interventions Exercise: Individual. Physical exercise program with neuromuscular facilitation techniques to improve
posture, inhibit rigidity, and ’conscientize’ movements
Control: Untreated.
Drug therapy was allowed to vary during trial.
Outcomes Webster Disability Scale.
Activity of daily living.
L-dopa reduction.
Not stated when examinations took place.
Notes Abstract only.
No means and SDs available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
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Cerri 1994 (Continued)
Similarity at Baseline Unclear risk Only information given was that all participants
were aged between 58 and 68 years and hadHoehn
and Yahr stage 3 and 4
Withdrawals Described Unclear risk Dropouts not described.
Cointerventions Constant Unclear risk 2 participants in the intervention group reduced
dose of L-dopa to avoid side effects. Allowed vari-
ation in medication
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Chandler 1999
Methods Parallel group design.
Randomisation method was not stated.
Method of analysis not described.
Treated at home, where they were assessed by a physiotherapist 5 times over a 12-month period. The
amount of physiotherapy was variable and depended on the participant’s needs
Assessed at baseline and during the duration of the trial (at 3, 6, 9, and 12 months) (see Outcomes)
Assessors were not blinded.
Participants 32 participants in the physiotherapy group and 35 in the control group. Dropouts 6 (physiotherapy),
9 (control)
Participants’ mean age 65 years (physiotherapy), 66 years (control). 31 males and 21 females completed
the study; Hoehn and Yahr for 47 of the participants, 2.6
Inclusion criteria: Idiopathic Parkinson’s disease, not receiving physiotherapy, no access (including self-
referral) to a physiotherapy review system. No exclusion criteria stated
Interventions Physiotherapy: individualised, based on holistic approach in which empowerment of participants and
caregivers was a strong element. Aimed to enhance the performance of activities. Gait and balance
exercises using verbal, auditory, and visual cues. Exercises to reduce stiffness, improve muscle tone,
and increase trunk rotation. Advice on transfers. Education in use of walking aids, reorganisation of
environment to reduce hazards and facilitatemovement. Leisure pursuits and social contacts encouraged
after strategies were adopted to facilitate these. Relaxation techniques (audio tapes and aromatherapy) to
improve sleep patterns. Aimed at reducing pain with education in postural awareness, exercise, TENS,
and acupuncture. Referral to other health professionals and social services for aids and appliances.
Control: untreated.
Drug therapy could vary.
Outcomes Functional Independence Measure*
Nottingham extended Activities Daily Living*.
UPDRS motor subsection*.
Timed walk*.
9-Hole peg test*.
SF-36 +.
PDQ-39 +.
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Chandler 1999 (Continued)
*Baseline, 3, 6, 9, 12 months.
+Baseline, 6, 12 months.
Not stated when during day examinations took place.
Notes Participants referred to other health professionals and social services during trial
Occupational therapy component to the physiotherapy.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Only gave information for age split by treatment
group.
Withdrawals Described High risk 22% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Drug therapy could vary.
Blinded Assessors High risk Assessors were not blinded.
de Bruin 2010a
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients 3 times per week for a 13-week period
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 16 participants in the cueing group and 17 participants in the control group. Dropouts 4 (cueing), 3
(control)
Participants’ mean age 64.1 years (cueing), 67.0 years (control); male/female 6/5 (cueing), 5/6 (control)
; Hoehn and Yahr 2.3 (cueing), 2.1 (control); mean duration of PD 6.4 years (cueing), 4.5 years
(control). No baseline characteristics were given for the dropout
Inclusion criteria: diagnosis of Parkinson’s disease (United Kingdom Brain Bank Criteria), Hoehn and
Yahr stage 2 to 3, stable medication regimen, independently mobile without the use of a walking aid,
and intact hearing. Exclusion criteria: diagnosis of less than 1 year, undergone deep brain stimulation
surgery, experience regular freezing episodes, unable to ambulate independently in the community,
presence of neurological disorders or comorbidities likely to affect gait, scoring 24 or less on theMMSE
and/or already listening to music
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de Bruin 2010a (Continued)
Interventions Cueing: Walking at a self-selected pace for 30 minutes, 3 times per week whilst listening to a preloaded
music battery on an MP3 player. The music battery was individualised for each participant matching
music preferences and the cadence of their preferred walking speed
Control: Continued with their regular activities.
Drug therapy was not described.
Outcomes Speed.
Stride time.
Stride length.
Cadence.
Stride time variability.
UPDRS (III) score.
Examined on medications at the same time of day.
Notes Compliance in the intervention group was good. 2 subjects in the music group took a 1 week break
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described High risk 21% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Low risk UPDRS evaluator was blinded to subject group
assignment.
de Bruin 2010b
Methods Parallel group design.
Method of randomisation was not stated.
Method of analysis not described.
Treated as outpatient 3 times per week for 13 weeks.
Assessed at baseline and post intervention.
Not stated whether assessors were blinded.
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de Bruin 2010b (Continued)
Participants 8 participants in the cueing group and 5 participants in the control group. No dropouts described
No baseline characteristics reported.
Inclusion criteria: Parkinson’s disease. No exclusion criteria
Interventions Cueing: Walking 3 times per week while listening to an individual music playlist. Playlists closely
matched each individual’s music preferences and preferred cadence
Control: Continued with their regular activities.
Drug therapy was not described.
Outcomes Spatiotemporal parameters approach, crossing and recovery steps of obstacle crossing were evaluated
using a GAITRite mat
Step speed.
Step length.
Not stated when during the day examinations took place.
Notes Abstract, only P values reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics reported.
Withdrawals Described Unclear risk No drop-outs described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Duncan 2012
Methods Parallel group design.
Online random number generator used to perform group allocations
Data analysed on an intention-to-treat basis.
Treated as outpatients for 104 hours over 12 months.
Assessed at baseline, 3 months, 6 months, and 12 months.
Assessor was blinded.
Participants 32 participants in the dance group and 30 participants in the control group were analysed. 6 dropouts
in dance group, 4 in control group
Participants mean age 70.6 years (dance), 69.2 (control). Mean Hoehn and Yahr stage 2.6 (dance), 2.5
(control). Male/female ratio 19/13 (dance), 16/14 (control). Duration of condition 5.4 years (dance),
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Duncan 2012 (Continued)
6.9 (control)
Inclusion criteria: Clinically defined ’definite PD.’ Exclusion criteria: serious medical condition, evi-
dence of abnormality other than PD-related changes on brain imaging (previously done for clinical
evaluations), history or evidence of musculoskeletal problem
Interventions Dance: tango class for 1 hour, twice weekly. Participants danced both leader and follower roles, changed
partners frequently, and learned new steps and/or integrated previously learned steps in new ways at
each class throughout the 12 months
Control: prescribed no exercise and told to go about living as usual
Outcomes MDS-UPDRS-III (primary).
MDS-UPDRS-II & I.
MiniBESTest balance test.
Freezing of gait questionnaire.
6-minute walk test
Gait speed.
Nine-hole peg test.
Participants were assessed while off medication (12-hour withdrawal)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria stated.
Randomisation Method Low risk Online random number generator.
Concealment of Allocation High risk Assigned by principal investigator using online
random number generator
Similarity at Baseline Low risk Baseline characteristics similar between groups.
Withdrawals Described High risk 16% withdrawals.
Intention To Treat Analysis Unclear risk Last observation carried forward.
Cointerventions Constant Low risk 12-hour withdrawal before assessment.
Blinded Assessors Low risk Assessor was blind to group allocation.
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Ellis 2005
Methods Cross-over design.
Block randomisation procedure was used in which each sealed envelope contained four Group A
assignments and four Group B assignments. This process continued until a total of 68 subjects were
randomly allocated
Method of analysis not described.
Treated as outpatients 2 times a week for 6 weeks for a total of 18 hours (1.5-hour sessions)
Assessed at baseline, immediately after 1st treatment. Immediately before 2nd treatment and 3 months
after 2nd treatment
Assessors were blinded.
Participants 35 participants in the physiotherapy group and 33 in the control group. 11 dropouts
Participants’ mean age 64 years (physiotherapy), 63 years (control); male/female ratio, 25/10 (physio-
therapy), 26/7 (placebo); mean Hoehn & Yahr 2.5 (physiotherapy), 2.4 (control)
Inclusion criteria: stable medication usage, Hoehn&Yahr stage 2 or 3, at least 1 score of 2 or more for at
least 1 limb for the tremor, rigidity, or bradykinesia item of the UPDRS, ability to walk independently,
age 35 to 75 years, no severe cognitive impairment (MMSE ≥24), no other severe neurologic, car-
diopulmonary, or orthopaedic disorders, not having participated in a physical therapy or rehabilitation
program in the previous 2 months. No exclusion criteria stated
Interventions Physiotherapy: 1.5-hour-long physical therapy session consisting of stretching, functional training, gait
training, auditory cueing, balance, recreational, and relaxation
Control: medical therapy only.
It was not stated whether drug therapy was kept constant during the trial
Outcomes Sickness Impact Profile (SIP-68).
UPDRS (Sections I, II, III).
Comfortable walking speed.
Assessments were performed at the same time of day and in the same order. Assessments were performed
in the ’on’ state for subjects who experience motor fluctuations
Notes Of the 68 subjects, 50 attended all treatment sessions.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Blocked randomisation (block size 8) with sealed
envelopes.
Concealment of Allocation High risk Sealed envelopes, which contained 8 group alloca-
tions (4 per group)
Similarity at Baseline Low risk
Withdrawals Described High risk 16% at the end of the trial.
Intention To Treat Analysis Unclear risk Method of analysis not described.
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Ellis 2005 (Continued)
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
Blinded Assessors Low risk Assessors were blind to group allocation.
Fisher 2008
Methods Parallel group design.
Randomisation was done by the subjects with their eyes closed; they selected a card corresponding to
one of the three groups
Method of analysis not described.
Treated as outpatients for 24 sessions over 8 weeks for both treatment arms, 6 sessions over 8 weeks for
control group
Assessed at baseline and immediately post treatment.
Assessors were blinded.
Participants 10 participants in the treadmill group, 10 participants in the physiotherapy group and 10 participants
in the control arm. No dropouts described
Participants’ mean age, 64.1 years (treadmill), 61.5 years (physiotherapy), 63.1 years (control). Male/
female ratio, 6/4 (treadmill), 5/5 (physiotherapy), 8/2 (control). Mean Hoehn and Yahr 1.9 in all 3
groups. Mean duration of PD 1.2 years (treadmill), 0.7 years (physiotherapy), 1.5 years (control)
Inclusion criteria: early-stage Parkinson’s disease, diagnosis of Parkinson’s disease within 3 years of study
participation, Hoehn and Yahr stage 1 or 2, 18 years or older, medical clearance from primary care
physician to participate in exercise programme, ability to walk. Exclusion criteria: medical or physical
screening examination showed a score of less than 24 on the MMSE, revealed physician-determined
major medical problems such as cardiac dysfunction that would interfere with participation; subjects
had musculoskeletal impairments or excessive pain in any joint that could limit participation in an
exercise programme, had insufficient endurance and stamina to participate in exercise 3 times per week
for a 1-hour session
Interventions Treadmill: Level of intensity was defined by MET. High-intensity exercise greater than 3 METs. Body
weight supported (BWS) treadmill training. Goal of each session was to reach andmaintain aMET > 3.
Exercise progressed by decreasing BWS (initially 10% of subject’s body weight) and physical assistance,
increasing the treadmill speed and time on the treadmill, with the end goal for each subject to walk on
the treadmill continuously for 45 minutes within the MET range
Physiotherapy: less than 3 METs. This group was representative of general or traditional physical
therapy. Each 45-minute session was individualised and consisted of activities from 6 categories: (1)
passive range of motion and stretching, (2) active range of motion, (3) balance activities, (4) gait, (5)
resistance training, (6) practice of functional activities and transitional movements
Control: zero intensity group. Six 1-hour education classes taken over an 8-week period
Drug therapy was constant during the trial.
Outcomes UPDRS (Total, I, II, and III subscores).
Hoehn and Yahr.
Functional assessments.
Walking test.
Sit-to-stand test.
Transcranial magnetic stimulation.
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Fisher 2008 (Continued)
All subjects took their customary medications at the same time relative to each assessment
Notes Subjects were allowed to continue their customary exercise routines and filled out a daily exercise diary
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Subjects self-selected a card with eyes closed.
Concealment of Allocation High risk Subjects self-selected a card with eyes closed.
Similarity at Baseline Low risk
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk All medication kept stable during course of study.
Credible Placebo Low risk Education classes attended by controls.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Ganesan 2010
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 8 hours over 4 weeks.
Assessed at baseline, and at 2 and 4 weeks.
Not stated whether assessors were blinded.
Participants Total of 20 participants.
No baseline characteristics were reported.
Inclusion criteria: idiopathic Parkinson’s disease, stable doses of dopaminomimetic drugs. No exclusion
criteria
Interventions Treadmill: partial weight supported treadmill gait training with 20% unweighing for 30 minutes per
day, 4 times per week
Control: did not receive any specific intervention.
Drugs were stable at time of randomisation.
Outcomes UPDRS.
Dynamic posturography.
Berg Balance Scale.
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Ganesan 2010 (Continued)
Tinetti performance orientated mobility assessment.
Tinetti balance score.
Gait score.
Participants were assessed in best ’ON’ state.
Notes Abstract only P values reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics were reported.
Withdrawals Described Unclear risk No information provided (abstract only).
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Only information provided was that drugs were
stable at time of randomisation
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Goodwin 2009
Methods Parallel group design.
Telephone randomisation external to the research team with 1:1 allocation in geographical cohorts
Data were analysed on an intention-to-treat basis.
Treated as outpatients for 10 hours over 10 weeks, then home exercise for 10 weeks
Assessed at baseline and at 20 and 30 weeks.
Assessors were not blinded.
Participants 64 participants in the exercise group and 66 in the control group. 7 dropouts in total
Participants’ mean age 72.0 years (exercise), 70.1 years (control). Male female ratio, 39/25 (exercise),
35/31 (control). Mean Hoehn and Yahr 2.6 (exercise), 2.4 (control). Mean duration of PD 9.1 years
(exercise), 8.2 years (control)
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease according to the UK Parkinson’s Disease
Society Brain Bank Criteria, self-reported history of two or more falls in the past year, able to mobilise
independently with/without a walking aid, resident in Devon, willingness to be randomly assigned and
provide written informed consent. Exclusion criteria: needed supervision or assistance from another
person to mobilise indoors, significant comorbidity that affects ability or safety to exercise (e.g. unstable
angina, unstable diabetes, significant postural hypotension, severe pain, significant dyskinesia), unable
to follow verbal or written instructions in English
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Goodwin 2009 (Continued)
Interventions Exercise: 10 weeks of supervised group strength and balance training plus 10 weeks of unsupervised
home exercises
Control: usual care.
Drug therapy could vary.
Outcomes Falls Incidence.
Number of fallers/recurrent faller.
Fall-related injuries.
Berg Balance Scale.
Timed Up and Go.
Fall Efficacy Scale International.
EQ-5D.
Household and recreational physical activity (Phone-FITT).
Not stated when examinations took place.
Notes Additional information and data obtained from author.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria stated.
Randomisation Method Low risk Telephone randomisation external to the research
team with 1:1 allocation in geographical cohorts
Concealment of Allocation Low risk Telephone randomisation external to the research
team with 1:1 allocation in geographical cohorts
Similarity at Baseline Low risk Characteristics of two groups similar.
Withdrawals Described Low risk 5% withdrawals.
Intention To Treat Analysis Low risk Data were analysed on an intention-to-treat basis.
Cointerventions Constant Unclear risk Participants changed theirmedication as appropri-
ate as part of usual care
Credible Placebo Unclear risk Control group received usual care.
Blinded Assessors High risk Assessors were not blinded.
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Haase 2011
Methods Parallel group design.
Block randomisation method used.
Analysed on a per protocol basis
Treated for a single session including 3 minutes of treatment
Assessment intervals not stated.
Assessors not blinded.
Participants 8 participants in the Finger tapping (FT) group, 12 in the Arm swinging group (AS) group, 6 in the
control group. 1 dropout from the FT group and 2 from the AS group
Participants’ mean age, 67 years (FT), 65 years (AS), 65 years (control); male/female 5/2 (FT), 5/5 (AS)
, 2/4 (control). Mean Hoehn and Yahr and mean duration of PD not stated. No baseline characteristics
were given for dropouts
Inclusion criteria: able to walk independently without assistive devices for at least 14 m at a time no
more than 4 times, Hoehn & Yahr stage 0 to 2. Exclusion criteria: severe perceptual deficits, medical
complications
Interventions Rhythmic finger tapping exercise: participants instructed to tap on a metal plate (while seated) to the
beat of an external auditory cue from a metronome set to 120% pretest walking cadence, for three, 1-
minute intervals with 30 seconds of rest between intervals
Rhythmic arm swing exercise: participants instructed to swing their arms (while seated) to the beat
from a metronome set to 120% pretest walking cadence, for three, 1-minute intervals with 30 seconds
of rest between intervals
Control: participants were instructed to remain seated for 4 minutes
Drug therapy not described.
Outcomes 9-Hole peg test.
UPDRS III & IV.
Berg Balance Scale.
Speed.
Stride length.
Cadence.
Notes Abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria stated.
Randomisation Method Unclear risk Method of generating blocks not stated.
Concealment of Allocation Unclear risk Method of randomisation not clear.
Similarity at Baseline Unclear risk Full baseline characteristics not stated.
Withdrawals Described High risk Dropouts 12%.
Intention To Treat Analysis High risk Per protocol analysis.
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Haase 2011 (Continued)
Cointerventions Constant Unclear risk Drug therapy not described.
Credible Placebo Low risk Control group received same time and attention
as intervention groups
Blinded Assessors High risk Assessors were not blinded.
Hackney 2009
Methods Parallel group design.
Randomisation was conducted by one author by selecting 1 of the 4 groups from a hat
Method of analysis not described.
Treated as outpatients for 20 hours within 13 weeks (1-hour sessions)
Assessed at baseline and within one week of completing 20 sessions
Assessors were blinded.
Participants 19 participants in the tango group, 19 in the waltz/foxtrot group, 17 in the Tai Chi group, and 20 in
the control group. 5, 2, 4 and 3 dropouts from the tango, waltz/foxtrot, Tai Chi, and control group
respectively
Participants’ mean age, 68.2 years (tango), 66.8 years (waltz/foxtrot), 64.9 years (Tai Chi), 66.5 years
(control); male/female 11/3 (tango), 11/6 (waltz/foxtrot), 11/2 (Tai Chi), 12/5 (control). Mean Hoehn
andYahr 2.1 (tango), 2.0 (waltz/foxtrot), 2.0 (TaiChi), and2.2 (control).Meandurationof PD6.9 years
(tango), 9.2 years (waltz/foxtrot), 8.7 years (Tai Chi), 5.9 years (control). No baseline characteristics
were given for dropouts
Inclusion criteria: Hoehn and Yahr stages 1-3, at least 40 years of age, could stand for at least 30
minutes, walk independently 3 or more metres with or without assistive device, diagnosis of idiopathic
Parkinson’s disease using diagnostic criteria for clinically defined ’definite PD’ based on published
standards, participants demonstrated clear benefit from levodopa, cognitively intact. Exclusion criteria:
history of neurological deficit other than Parkinson’s disease, dementia, another measure of cognitive
function, and a separate part of the study not reported where all participants were required to perform
a subtraction task while walking (all completed with 85% accuracy), considered cognitively intact
Interventions Dance: experienced professional ballroom dancer taught progressive tango or waltz/foxtrot lessons for
1 hour twice weekly. Instructor equally versed in both dances attempted to give all students equal
attention. Both genders spent equal time leading and following dance roles. All steps done in closed
practice position where participants maintain contact through upper extremities and face one another
Martial arts: Received progressive lessons for 1 hour twice weekly on Tai Chi’s first and second circles
including 37 postures of the Yang Short Style of Cheng Manching from an experienced instructor
Control: No intervention.
Drug therapy was kept constant during the trial.
Outcomes PDQ-39.
UPDRS III.
Berg Balance Scale.
Timed Up and Go.
6-Minute walk test.
Freezing of gait questionnaire.
Forward and backward gait.
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Hackney 2009 (Continued)
Gait speed.
Stride length.
Single support time.
Exit questionnaire.
Tandem Stance Test (TS).
One-Leg Stance test (OLS).
Assessments took place at a standardised time, when participants were in the ’on’ state
Notes 1 participant was excluded from the study as the result of medication change. Participants were in-
structed not to change their habitual exercise routines
Data taken from all three publications.
The tango and waltz/foxtrot arms assessed were suitably similar and were therefore combined to give
one comparison of dance
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Conducted by one author by selecting 1 of the 4
groups from a hat
Concealment of Allocation High risk Conducted by one author by selecting 1 of the 4
groups from a hat
Similarity at Baseline Low risk
Withdrawals Described High risk 19% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drug therapy was kept constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Homann 1998
Methods Parallel group design.
Participant’s names were put into alphabetical order and then randomised using computer-generated
random number tables
Method of analysis not described.
Treated as outpatients for 14 ’units’ over 5 weeks.
Assessed at baseline and immediately after treatment.
Not stated whether assessors were blinded.
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Homann 1998 (Continued)
Participants 8 participants in physiotherapy group and 7 in placebo group. No dropouts were described
No baseline characteristics available from abstract.
Inclusion criteria: idiopathic Parkinson’s disease according to UK Brain Bank diagnostic criteria. No
exclusion criteria
Interventions Physiotherapy: individual Bobath program focusing on proprioceptive skills to improve posture and
gait
Control: untreated.
Drugs were stable for duration of therapy.
Outcomes UPDRS.
Axial symptoms.
Stride length.
Walk speed.
Stride cadence.
Notes Abstract and poster only.
No numerical data available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Participant’s names were put into alphabetical or-
der and then they were randomly assigned using
computer-generated random number tables
Concealment of Allocation Low risk Based on information above, assumed treatment
allocation performed once all patients recruited
Similarity at Baseline Unclear risk No baseline characteristics available from abstract.
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drugs were stable for duration of therapy.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
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Keus 2007b
Methods Parallel group design.
Randomised in blocks of four in order of enrolment. Independently assigned with concealed allocation
The data was analysed on an intention-to-treat analysis.
Treated as outpatients for an unspecified time, once or twice weekly for 10 weeks
Assessed at baseline and immediately after treatment.
Assessor was blinded.
Participants 14 participants in the physiotherapy group and 13 in the control group. 1 dropout from the control
group
Participants’ median age, 65 years (physiotherapy), 71 years (control). Male:female ratio, 11/3 (phys-
iotherapy), 11/2 (control). Mean Hoehn and Yahr 2.4 in both groups. Mean duration of PD 7 years
(physiotherapy), 6 years (control)
Inclusion criteria: idiopathic Parkinson’s disease according to the UK Parkinson’s Disease Society Brain
Bank Criteria, stable reaction to anti-Parkinsonian medication, at least one mobility-related activity
limitation within core areas of physiotherapy practice in Parkinson’s disease (gait, balance, posture,
and transfers) experienced by the participant as important. Exclusion criteria: Hoehn and Yahr stage
5 during the ’on’ period, physiotherapy within 4 months before randomisation, severe comorbidity
influencing mobility or life threatening (e.g. cancer), not motivated to participate in physiotherapy,
severe cognitive impairment defined by an MMSE score ≤ 24, presence of psychiatric impairments
Interventions Physiotherapy:Once- or twice-weekly individual physiotherapy sessions.Delivered by a physiotherapist
trained in the use of evidence-based practice guidelines. Interventions included Parkinson’s disease
specific techniques such as cueing, cognitive movement strategies, and general techniques such as
training of balance, leg strength, and physical fitness. The intervention targeted balance, transfers,
posture, and gait, dependent on the participant’s main complaint
Control: no physiotherapy.
It was not stated whether drug therapy was kept constant during the trial
Outcomes Patient preference outcome scale.
The Parkinson Activity Scale.
Mobility domain of the Dutch validated version of the Parkinson’s disease questionnaire
Assessments took place during the participants’ subjectively best ’on’ phase
Notes Most participants received six to thirteen sessions of physiotherapy in the nine-week period
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Block size of 4.
Concealment of Allocation Unclear risk Independently assigned with concealed allocation.
Similarity at Baseline Low risk
Withdrawals Described Low risk 1 dropout from control group (4%).
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Keus 2007b (Continued)
Intention To Treat Analysis Low risk Data were analysed according to intention-to-treat
principles
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
Blinded Assessors Low risk Assessor was blind to group allocation.
Klassen 2007
Methods Parallel group design.
Randomisation method was not stated.
Method of analysis not described.
Treated as outpatients for 45 hours (exercise and education), 30 hours (exercise only) over 12 weeks
Assessed at baseline, immediately, and 3 months after treatment
Assessors were blinded.
Participants 9 participants in the exercise and education group, 9 in the exercise group, and 8 in the control group.
1 dropout (exercise and education), 1 (exercise), 2 (control)
Median age 62 years (exercise and education), 70 years (exercise), 66.5 years (control). Male/female
ratio, 7/2 (exercise and education), 5/3 (exercise), 5/1 (control). Hoehn and Yahr 1.9 (exercise and
education), 1.4 (exercise), 1.5 (control). Years since diagnosis 4 years (exercise and education), 3 years
(exercise), 7 years (control). No baseline characteristics given for dropouts
Inclusion criteria: clinical diagnosis of Parkinson’s disease, 40 to 80 years of age,Hoehn andYahr stages 1
to 3. Exclusion criteria: medical conditions that limit physical activity, dementia, or significant cognitive
impairment. MMSE < 20, depression or other psychiatric disorder. Beck Depression Inventory II score
> 20, other neurological conditions
Interventions Exercise and education: 1 hour and 15 minutes weekly of education delivered by physiotherapist,
occupational therapist, speech language therapist, dietician, clinical psychologist, and social worker.
Education consisted of active learning methods, action plan development, and discussion to complete
each session. Report and discussion of action plan success/barriers to success at beginning of each
session. An hour and 15 minutes twice weekly sessions of exercise, which consist of warm-up, cool-
down, flexibility, and strengthening exercises, posture and balance training, progressive aerobic training,
and functional task training (e.g. sit-to-stand)
Exercise: as above, an hour 15 minutes twice weekly.
Control: no intervention.
It was not stated whether drug therapy was kept constant during the trial
Outcomes PDQ-8.
Stanford self-efficacy for managing chronic disease scale.
North Western University Disability Scale.
Schwab and England ADL Scale.
Activities Balance Confidence Scale.
Timed Up & Go.
Not stated when examinations took place.
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Klassen 2007 (Continued)
Notes Abstract and presentation slides only.
The education and exercise and exercise only arms assessed were suitably similar and were therefore
combined to give one comparison of exercise
Average attendance of the education and exercise classes ranged from 79.4% to 85.5%
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described High risk 15% withdrawals
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk It was not stated whether drug therapy was kept
constant during the trial
Blinded Assessors Low risk Assessors were blinded to group allocation.
Kurtais 2008
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients 3 times a week for 6 weeks for a total period of 12 hours (40-minute sessions)
Assessed at baseline and 7 weeks after baseline assessments.
Assessors were blinded.
Participants 13 participants in the treadmill group and 14 in the control group. 1 dropout in the treadmill group
and 2 in the control group
No baseline characteristics given for dropouts. Participants’ mean age 63.8 years (treadmill), 65.7 years
(control); male/female 5/7 (treadmill), 7/5 (control); Hoehn and Yahr 2.5 (treadmill), 2.2 (placebo).
Duration of PD 5.3 years (treadmill), 5.4 years (control)
Inclusion criteria: stable antiparkinsonian medication, ability to walk independently, not participated
in a rehabilitation program in the previous 3 months
Exclusion criteria: severe cognitive impairments or severe musculoskeletal, cardiopulmonary, neuro-
logical, or other system disorders
Interventions Treadmill: gait training on a treadmill 3 times a week, attaining 70% to 80% of maximal heart rate.
Either speed or incline was gradually increased over time
Control: untreated.
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Kurtais 2008 (Continued)
Drug therapy was stable during the trial.
Outcomes 20-m walking time.
Timed U-turn task.
Turning around a chair.
Climbing up and down a flight of stairs at participants’ preferred speed
Standing on one foot.
Standing up from an armless chair.
Rate global physical status.
Cardiopulmonary fitness levels.
Examinations were done during the participants ’on’ phase.
Notes Both groups were taught exercises to maintain flexibility and range of motion
One patient from the treadmill group was excluded as the result of noncompliance
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described High risk 11% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drug therapy was stable during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Lehman 2005
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 10 days over 2 weeks.
Assessed at baseline, immediately after, 1 week after and 1 month after intervention
Participants 5 participants in the cueing group and 6 participants in the control group. No dropouts described
Participants’ mean age, 78 years (cueing), 74 years (control). Male/female ratio, 4/1 (cueing), 4/2
(control). Mean Hoehn and Yahr not stated. Duration of PD 7 years (cueing), 6.1 years (control)
Inclusion criteria: participants with gait impairment due to Parkinson’s disease, early-stage Parkinson’s
disease. Exclusion criteria: persons with other neurological and/or orthopaedic impairments who could
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Lehman 2005 (Continued)
not walk the distances required of the training program were excluded
Interventions Cueing: 10-day training programme of walking 1800 feet per day with instructions to ’take long steps.
’ One trip down the 30-foot pathway is a length. Each training set consisted of 20 lengths. Participants
completed three training sets each day
Controls: no change in lifestyle or medication.
Drug therapy was not described.
Outcomes Step length.
Speed.
Cadence.
Examinations took place at the same time each day.
Notes Data on graphs limited data.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Mak 2008
Methods Parallel group design.
Participants randomly allocated to groups by drawing lots.
Method of analysis not described.
Treated as outpatients for 4 hours (audio-visual), 6 hours (exercise) over 4 weeks
Assessed at baseline, at 2 weeks, immediately after, and 2 weeks after treatment had ended
Assessor was blinded.
Participants 21 participants in the cueing group, 21 participants in the exercise group, and 18 in the control group.
2 dropouts from the cueing group, 2 from the exercise group, and 4 from the control group
No baseline characteristics given for dropouts. Participants’ mean age 63 (cueing), 66 (exercise), 63
(control). No data given for the sex of participants. Hoehn and Yahr stage 2.8 (cueing), 2.7 (exercise),
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Mak 2008 (Continued)
and 2.7 (control). Duration of PD 5.9 years (cueing), 6.1 years (exercise), 5.9 years (control)
Inclusion criteria: diagnosed with Parkinson’s disease according to Quinn, stable on anti-Parkinson’s
disease medications without dyskinesia, orthopaedic, arthritic, or heart problems, aged between 50 and
75 years, perform sit-to-stand independently, can follow instructions. No exclusion criteria stated
Interventions Cueing: audiovisual cued task-specific training for 20 minutes three times per week. Received cued sit-
to-stand training using Equitest-Balance Master. Visual cue was given on a computer screen with verbal
command as auditory cue. Each task lasted 2 minutes, repeated once with 30-second rests in between
Exercise: 45 minutes of conventional exercise twice a week. Conventional mobility and strengthening
exercises for flexors and extensors of trunk, hips, knees, and ankles, followed by sit-to-stand practice
Control: no treatment.
Drugs stable during therapy.
Outcomes Peak horizontal speed (used in meta-analysis).
Peak vertical speed.
Movement time.
3D kinematics data of sit-to-stand.
Not stated when during the day tests took place.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Drawing lots.
Concealment of Allocation High risk Drawing lots.
Similarity at Baseline Low risk
Withdrawals Described High risk 13% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drugs stable during therapy.
Blinded Assessors Low risk Assessor was blinded to group allocation.
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Marjama-Lyons 2002
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 24 hours over 12 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 30 participants. No dropouts were described.
No baseline characteristics available.
Inclusion criteria: levodopa-responsive Parkinson’s disease, Hoehn and Yahr stage 1.5 to 3. No exclusion
criteria
Interventions Martial arts: two one-hour weekly Tai Chi classes.
Control: continued baseline exercise program and added no new exercises
Drug therapy was stable during the study.
Outcomes UPDRS motor score (part III).
Fall frequency form.
Balance master Limits of Stability.
Global Assessment of Change.
Examinations took place when participants were in the ’on’ state
Notes All subjects did not practice Tai Chi before entry.
Abstract. No means and SDs, just P values available.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk No baseline characteristics provided.
Withdrawals Described Unclear risk Dropouts not described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Drug therapy was stable during study.
Blinded Assessors Low risk Assessors were blinded to group allocation.
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Meek 2010
Methods Parallel group design.
Participants were randomly assigned using computer-generated random block sizes of four
The data were analysed on an intention-to-treat basis.
Treated as outpatients for 12 sessions over 12 weeks.
Assessed at baseline and immediately after treatment, and at 6 months
Assessor was blinded.
Participants 20 participants in the exercise group and 19 in the control group. 1 dropout in the control group
Participants mean age, 63.4 years (exercise), 64.9 years (control); male/female ratio 15/5 (exercise), 16/
3 (control); mean duration of PD 5.1 years (exercise), 4.7 (control). Mean Hoehn and Yahr was not
reported
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease, aged 18 years or over, no cognitive, sensory,
or psychological impairments that may prevent engagement in participation in the study or that put
the participant at risk (judged by the referring clinician), able to participate in the study for its full
duration, able to walk 10 m using any aid or assistance required. Exclusion criteria: participants unable
to meet inclusion criteria, or those unwilling to participate, participants with additional impairments
resulting in restriction of mobility, or any contraindications to exercise
Interventions Exercise: collaborated with fitness instructors to design a 3-month individualised, progressive exercise
program
Control: received usual care.
Drug therapy was allowed to change during the study.
Outcomes Physical Activity Scale for the Elderly.
Accelerometer monitored physical activity.
10-m walk test.
2-minute walk test.
Lower limb muscle strength and grip strength.
Fatigue severity scale.
PDQ-39.
Falls.
No constraints on timing of assessments.
Notes Abstract and further information provided by author.
Gym attendance during the pooled intervention periods was high overall, with a mean of 14.5 visits
and a median of 12 visits
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated random block sizes of four.
Concealment of Allocation Low risk Randomisation done centrally.
Similarity at Baseline Low risk
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Meek 2010 (Continued)
Withdrawals Described Low risk 1 dropout in the control group (3%).
Intention To Treat Analysis Low risk Intention-to-treat analysis.
Cointerventions Constant Unclear risk Drug therapy was allowed to change during the
study.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Nieuwboer 2007
Methods Cross-over design.
Participants were randomly allocated in permuted blocks of six to an early or late intervention group
by an independent investigator not involved in data analysis. Allocation was concealed by the use of
opaque sealed envelopes
The data were analysed on an intention-to-treat basis.
Treated at home for 4.5 hours over 3 weeks.
Assessed at baseline, immediately after 1st and 2nd treatment, and at 12 weeks
Assessors were blinded.
Participants 76 participants in the cueing group and 77 in the control group. 1 dropout in the cueing group
Participants’ mean age, 66.9 years (cueing), 67.2 years (control). Male/female ratio 48/28 (cueing), 40/
37 (control). Hoehn and Yahr 2.7 (cueing), 2.8 (control). Mean duration of PD 7 years (cueing), 8
years (control)
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease (defined by the UK Brain Bank Criteria),
Hoehn and Yahr stage 2 to 4, showing mild to severe gait disturbance with score > 1 on the UPDRS
item 29, stable drug usage, age 18 to 80 years. Exclusion criteria: undergone deep brain stimulation
or stereotactic neurosurgery, had cognitive impairment (MMSE < 24), had disorders interfering with
participation in cueing training, including neurological (stroke, multiple sclerosis, tumour), cardiopul-
monary (chronic obstructive disorders, angina pectoris), and orthopaedic (osteoarthritis, rheumatoid
arthritis, and back pain) conditions, had predictable and long-lasting off periods (score 1 on item 37
and score > 2 on item 39 on UPDRS). Had participated in a physiotherapy programme 2 months
before starting the trial
Interventions Cueing: cueing programme delivered at home over 3 weeks by 1 therapist in 9 sessions lasting 30
minutes. A prototype cueing device specifically developed for the study provided 3 rhythmical cueing
modalities: 1. auditory (a beep delivered through an ear piece), 2. visual (light flashes delivered through
a light-emitting diode attached to a pair of glasses), 3. somatosensory (pulsed vibrations delivered by a
miniature cylinder worn under a wristband). Participants tried all cueing modalities in the first week,
but trained with their preferred modality. Cued practice was applied during a variety of tasks and aimed
to improve step length and walking speed, prevent freezing episodes, and improve balance
Control: no training.
Drug therapy was kept constant throughout the trial.
Outcomes Posture and gait score.
Gait and balance measures (including 10-m test of walking, gait speed, step length, step frequency,
functional reach, timed single leg and tandem stance, Freezing of Gait Questionnaire, Timed Up and
Go Test
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Nieuwboer 2007 (Continued)
Activity measures (including Nottingham Extended Activities of Daily Living Index, Falls Efficacy
Scale)
Participation measures (including Parkinson’s Disease Questionnaire-39, Carer Strain Index)
Falls diary.
Assessments were performed at the same time of day when participant was in the ’on’ phase approxi-
mately 1 hour after drug intake
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Permuted block size of 6.
Concealment of Allocation High risk Sealed envelopes.
Similarity at Baseline Low risk
Withdrawals Described Low risk 1 dropout in the cueing group (< 1%).
Intention To Treat Analysis Low risk The data were analysed on an intention-to-treat
basis.
Cointerventions Constant Low risk All medication remained constant.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Protas 2005
Methods Parallel group design.
Method of randomisation not stated.
Method of data analysis not described.
Treated as outpatients for 24 hours over 8 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 9 participants in both groups. No dropouts described.
Participants’ mean age 71.3 years (treadmill), 73.7 years (control); male/female all male subjects for
both groups. MeanHoehn and Yahr 2.8 (treadmill), 2.9 (control). Duration of PD 7.1 years (treadmill)
, 8.1 years (control)
Inclusion criteria: idiopathic Parkinson’s disease, postural instability-gait difficulty predominant Parkin-
son’s disease, experiences with freezing episodes, and/or history of falls, stable regimen of antiparkin-
sonian medications, ability to stand and walk with or without assistance, stage 2 or 3 Hoehn and
Yahr, scores of moderate or higher on all scales on the Neurobehavioural Cognitive Status Examination
(Cognistat). No exclusion criteria
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Protas 2005 (Continued)
Interventions Treadmill: gait and step training 3 times per week. Using a harness for safety, the participant walks
forward on a treadmill at fastest speed for 5 to 7 minutes, backwards at fastest self-selected speed for
5 to 7 minutes. Then left and right sideways walking at fastest selected speed for 2 to 3 minutes each
way. Participants then had 5 minutes of rest before starting step training, which consisted of turning
on the treadmill suddenly to perturb the participant’s standing balance (15-20 forward and backward
perturbations, 10-15 left and right perturbations)
Control: no intervention.
Drug therapy was stable throughout the trial.
Outcomes Gait speed.
Cadence.
Stride length.
5-Step test.
Reports of falls.
Freezing of gait.
Assessments took place when participants were at their best ’on’ state
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of data analysis not described.
Cointerventions Constant Low risk Drug therapy was stable throughout the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
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Purchas 2007
Methods Cross-over design.
Method of randomisation not stated.
Method of data analysis not described.
1 session per week for a total of 12 weeks.
Assessed at baseline and immediately after 1st and 2nd treatments
Not stated whether the assessors were blinded.
Participants 10 participants in the martial arts group and 10 participants in the control group. One dropout from
both groups
Mean age of participants 70 years in both groups. Male/female ratio, 7/2 (martial arts), 4/5 (control).
Mean Hoehn and Yahr 2 (martial arts), 2.3 (control). No baseline characteristics given for dropouts
Inclusion criteria: maintenance phase of Parkinson’s disease. No exclusion criteria
Interventions Martial arts: 1-hour weekly Tai Chi training.
Control: no treatment.
Drug therapy not described.
Outcomes Timed Up and Go Test.
PDQ-39.
UPDRS.
Hoehn and Yahr stage.
Falls diary.
Not stated when during the day examinations took place.
Notes Abstract and poster only.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Unclear risk Maintenance phase of Parkinson’s disease.
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described Low risk 10% dropout
Intention To Treat Analysis Unclear risk Method of data analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
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Sage 2009a
Methods Parallel group design.
Method of randomisation not stated.
Data analysed on an intention-to-treat basis.
Treated as outpatients for 18 hours (exercise), 20 to 24 hours (PDSAFEx) over 10 to 12 weeks
Assessed at baseline and after treatment.
Assessors were blinded.
Participants 17 participants in the exercise group, 21 participants in the PDSAFEx group, and 15 in control. 4
dropouts (exercise) and 3 dropouts (PDSAFEx)
Participants’ mean age 65.1 years (exercise), 64.2 years (PDSAFEx), 68.6 years (control). Male/female
ratio, 6/7 (exercise), 12/6 (PDSAFEx), 7/8 (control). Hoehn and Yahr score not given. Duration of PD
3.2 years (exercise), 4.7 years (PDSAFEx), and 2.5 years (control). No baseline characteristics given for
dropouts
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease with no othermajormedical, physiological,
or neurological problem, a stable medication schedule, mild to moderate Parkinson’s disease defined as
a score of less than 35 on UPDRS motor section
Interventions Exercise: lower limb aerobic training, exercise for 30minutes (5-minwarm-up, 20-min aerobic training,
5-min cool-down) three times a week in groups of 4 on Biostep semi-recumbent elliptical’s in the seated
position. The machine was primarily leg driven with arms moving in a coordinated pattern. Intensity
maintained by achieving a pace of 50 RPM, a heart rate of 60% to 75% of age-related max, and a Borg
rate of perceived exertion of below 5
PDSAFEx: sensory attention focused exercise for 40 to 60 minutes three times a week. 20 to 30
minutes of nonaerobic gait exercises focused on body coordination, followed by 20 to 30 minutes of
sensory attention exercises using latex Thera-bands attached to arm rests of office chairs. Exercises were
completed with eyes closed and cued to the sensory feedback from specific portions of each exercise.
Examples of exercises, tandem walking for balance and coordination, side stretches down side of chair
for sensory feedback
Control: Nonexercise control group, maintained regular activity level
Drug therapy remained unchanged during the trial.
Outcomes UPDRS III.
Timed Up and Go.
Spatiotemporal aspects of gait.
Assessments took place when participants were at ’peak’ dose (approximately 90 min after administra-
tion)
Notes 3-arm trial.
The PD SAFEx and exercise arms assessed were suitably similar and were therefore combined to give
one comparison of exercise
Both exercise groups attended an equivalent number of training sessions, overall 90%
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
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Sage 2009a (Continued)
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described High risk 13% withdrawals.
Intention To Treat Analysis Low risk Statisicial analysis was done using intention-to-
treat principles
Cointerventions Constant Low risk Drug therapy remained unchanged during the
trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Schenkman 1998
Methods Parallel group design.
Participants were stratified according to gender and then randomly assigned using computer-generated
assignment
Randomisation schedule kept in office of statistician until participants were assigned
Method of data analysis not described.
Treated as outpatients for 30 hours over 10 to 13 weeks.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 27 participants in exercise group, 24 participants in control group. 4 dropouts from exercise group, 1
from control group
No baseline characteristics given for dropouts. Participants mean age 70.6 years (exercise), 71.2 years
(control); male/female 18/5 (exercise), 16/7 (control); Hoehn and Yahr 2.6 (exercise), 2.7 (control)
Inclusion criteria: Parkinson’s disease as diagnosed by a neurologist, Hoehn and Yahr stage 2 or 3,
functional axial rotation of 120 degrees or less to either side.
Exclusion criteria: hospitalised within past 3 months, PD drugs changed in last month, other neuro-
logical disorders, Folstein MMSE < 23
Interventions Exercise: individual exercises to improve spinal flexibility and coordinated movement. Standardised
programme included a series of exercises divided into 7 graduated stages, from supine to standing.
Exercises learned at each stage are continued throughout with progressively higher level activities added.
Exercises are incorporated into daily routine at end of formal training sessions
Control: no treatment. (’Wait listed’ for exercise programme)
Drug therapy constant during trial.
Outcomes Functional axial rotation.
Functional reach.
Timed tests.
Timed walk.
Cervical and lumbar range of motion.
Walking speed.
Participants with fluctuations assessed during ’on’ time.
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Schenkman 1998 (Continued)
Notes Abstract, further information obtained from author.
All 46 participants completed 30 treatment sessions within their allotted time
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated assignment.
Concealment of Allocation Low risk Randomisation schedule kept in office of statisti-
cian until participants were assigned
Similarity at Baseline Low risk
Withdrawals Described Low risk 10% withdrawals.
Intention To Treat Analysis Unclear risk Method of data analysis not described.
Cointerventions Constant Low risk Drug therapy was kept constant during the trial.
Blinded Assessors Low risk Assessors were blinded to group allocation.
Schilling 2008
Methods Parallel group design.
Participants were gender matched, then randomly assigned. Method of randomisation not stated
Method of data analysis not described.
Treated as outpatients for 16 sessions of an unspecified time over 8 weeks
Assessed at baseline and immediately after treatment.
Participants 9 participants in the exercise group and 9 participants in the control group. 1 dropout form the exercise
group, 2 dropouts from the control group
Participants’ mean age 61.3 years (exercise), 57 years (control); male/female 5/4 (exercise), 6/3 (control)
; Hoehn and Yahr 2.1 (exercise), 1.9 (control)
Inclusion criteria: mild to moderate Parkinson’s disease, Hoehn and Yahr stage 1 to 2.5, ability to walk a
20-foot path, turn, and return to the start without use of assistive device. Exclusion criteria: orthostatic
hypotension, dementia (MMSE < 24), other significant comorbidities (i.e. stroke, severe degenerative
osteoarthritis), other causes of Parkinsonism such as PSP, vascular PD, and multiple-system atrophy as
determined by board-certified neurologist
Interventions Exercise: moderate volume, high-load lower-body resistance training twice weekly. After a warm-up,
participants performed three sets of 5 to 8 repetitions for the leg press, seated leg curl, and calf press
under direct supervision of a Certified Strength and Conditioning Specialist. Subjects were instructed
to lift the weight as fast as possible with good form and to slowly return the weight to the start position.
Progression was planned so that when eight repetitions could be completed for all the sets, the weight
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Schilling 2008 (Continued)
was increased by 5% to 10%
Control: Continue standard care.
Drug therapy was not described.
Outcomes Maximum strength for the lower body.
Activities-specific balance confidence.
Timed Up and Go.
6-minute walk test.
All testing done when participants were in their optimally medicated state, typically within 30 minutes
to 2 hours of their first morning dose
Notes Control group given the opportunity to complete the training intervention after the 8-week control
period
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
Similarity at Baseline Low risk
Withdrawals Described High risk 17% withdrawals.
Intention To Treat Analysis Unclear risk Method of data analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Schmitz-Hubsch 2006
Methods Parallel group design.
Participants were sorted randomly, matched for disease severity, presence or absence of dyskinesia, and
type of clinical manifestation. Randomisation was carried out using a list of pseudonyms generated by
one investigator and transferred by fax to a 2nd investigator
The data were analysed on an intention-to-treat basis.
Treated as outpatients for 8 hours over 8 weeks, then for 0 hours for 8 weeks, then 8 hours for 8 weeks.
Total of 16 hours over 24 weeks
Assessed at baseline, 3, 6, and 12 months.
Not stated whether assessors were blinded.
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Schmitz-Hubsch 2006 (Continued)
Participants 32 participants in the martial arts group and 24 in the control group. 2 dropouts in the martial arts
group and 5 in the control group
Participants’ mean age, 64 years (martial arts), 63 years (control); male/female 24/8 (martial arts), 19/
5 (control). Hoehn and Yahr score not given. Duration of PD 6 years (martial arts) and 5.6 years
(control)
Inclusion criteria: participants diagnosed with Parkinson’s disease according to the UK Brain Bank
Criteria at any stage of the disease with or withoutmotor complications,MMSE>24. Exclusion criteria:
previous practical experience with Qigong, recent (< 1 month), or planned change of medication, signs
of central nervous system disease other than Parkinson’s disease (e.g. aphasia, dementia) (defined by
MMSE < 24)
Interventions Martial arts: 1-hour weekly group lesson of Qigong delivered by an experienced teacher. Exercises
were carried out standing or in the sitting position adjusted to participants’ physical abilities. Teacher
repeatedly stressed importance of home self-exercise
Control: no intervention.
Drug therapy varied throughout the trial.
Outcomes UPDRS III.
PDQ-39.
Montogmery-Asperg Depression Rating Scale.
Nonmotor symptoms.
Self-reporting questionnaire.
Assessments were carried out when participants were in the ’on’ state (time of optimal medication effect
as defined by the participant). Follow-up assessments were done at similar times of the day
Notes Participants were asked not to change their medication during the study, but if their medical condition
required adaptations, this would not lead to exclusion
Compliance at one year follow-up was fair.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk List of pseudonyms.
Concealment of Allocation High risk Randomisation was carried out using a list of
pseudonyms generated by one investigator and
transferred by fax to a 2nd investigator
Similarity at Baseline Low risk
Withdrawals Described High risk 13% withdrawals.
Intention To Treat Analysis Low risk All analyses were carried out on an intention-to-
treat-basis
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Schmitz-Hubsch 2006 (Continued)
Cointerventions Constant Unclear risk Drug therapy varied throughout the trial.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Shankar 2008
Methods Parallel group design.
Random allocation using computer-generated random list.
Method of analysis not described.
Treated as an outpatient for 36 hours over 3 months.
Assessed at baseline and immediately after treatment.
Assessors were blinded.
Participants 14 participants in the cueing group and 14 in the control group. No dropouts described
Participants’ mean age, 70 years (cueing), 62 years (control); male/female 6/8 (cueing), 8/6 (control),
mean Hoehn and Yahr score 2.4 (cueing), 2.3 (control). Duration of PD 7.5 years (cueing), 7.9 years
(control)
Inclusion criteria: diagnosis of idiopathic Parkinson’s disease as per UK Brain Bank criteria, Hoehn &
Yahr disease stages 2 and 3, stable Parkinson’s disease medication for 1 month before baseline visit,
ability to walk with headphones unaided for 30 minutes three times per week, absence of pre-existing
walking to music. Exclusion criteria: presence of dementia (MMSE < 26), presence of comorbidities
that affect the ability to walk, hearing deficits
Interventions Cueing: walking for 30 minutes three times per week while listening to a battery of musical pieces.
Music was self-selected based on participant input and was cadence-matched to the participant’s ideal
walking speed
Control: maintained their normal walking activity.
Minor medication changes allowed, as deemed appropriate by team neurologist
Outcomes Gait and Balance Scale.
UPDRS III.
Adjusted PDQ-39.
Activities-Specific Balance Confidence Scale.
Not stated when examinations took place.
Notes Abstract. Information on trial quality and data obtained from author
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Low risk Computer-generated random list.
Similarity at Baseline Low risk
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Shankar 2008 (Continued)
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Minor medication changes allowed, as deemed ap-
propriate by team neurologist
Blinded Assessors Low risk Assessors were blinded to group allocation.
Shankar 2009
Methods Parallel group design.
Randomisation method not stated.
Method of analysis not described.
Treated as outpatients for 8 hours over 8 weeks.
Assessed at baseline and immediately after treatment.
Assessor was blinded.
Participants 10 participants in the treadmill + cueing group, 10 participants in the cueing group. No dropouts
described
Baseline characteristics given only for all three treatment groups combined, Mean age 64.4 years, 62%
were male
Inclusion criteria: moderate Parkinson’s disease. No exclusion criteria
Interventions Treadmill + cueing: walking on the treadmill with music for 30 min twice a week. Music was selected
on the basis of participant input and was cadence-matched to the participant’s preferred walking speed
Treadmill: walking on the treadmill without music for 30 minutes twice a week
Cueing: listening to music for 30 minutes twice a week.
Drug therapy was not described.
Outcomes Gait and Balance Scale.
UPDRS III.
PDQ-39.
Not stated when examinations took place.
Notes Abstract only.
The 3rd arm, treadmill only, was excluded from our analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Unclear risk Baseline characteristics given only for all three
treatments groups combined
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Shankar 2009 (Continued)
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk Drug therapy was not described.
Credible Placebo Low risk
Blinded Assessors Low risk Assessor was blinded to group allocation.
Stack 2012
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not stated.
Treated at home for 12 hours over 4 weeks.
Assessed at baseline, 4 weeks, 8 weeks and 12 weeks.
Assessors blinded for all outcomes with the exception of forward reaches (FR)
Participants 24 participants in physio group, 23 participants in control group. 8 drop-outs in physio group, 4 in
control group
Participants median age 75 years (physio), 74 years (control). Male/female ratio 17/7 (physio), 18/5
(control). Hoehn and Yahr 1.3 (physio), 1.7 (control). Duration of condition (median) 8 years (physio)
, 7 (control)
Inclusion criteria: Parkinson’s disease as per UK Brain Bank criteria, willing and able to take part in
intervention, willing and able to complete outcome measures, score of at least 8/12 on the Middlesex
elderly assessment of mental state, Hoehn and Yahr I-IV, self report chair transfers as excessively slow
or requiring much effort, assistance or repeated attempts or associated with a previous fall
Interventions Physio: Home-based physiotherapy programme focused on chair transfers. Supervised exercises to
enhance hip and knee extensor strength and trunk stability and flexibility. Teaching and learning
movement strategies for safer and easier standing and sitting. Verbal cueing
Control: No physiotherapy.
Outcomes PAS chair transfer.
Sit-to-stand time.
SAS score.
SS-180 turn time.
Forward reach.
UPDRS posture.
HR-QOL.
Assessed in “ON” phase.
Notes Data reported as median (IQR).
Risk of bias
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Stack 2012 (Continued)
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Inclusion criteria stated.
Randomisation Method Unclear risk Method not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
Similarity at Baseline Low risk Baseline characteristics similar in both arms.
Withdrawals Described High risk 26% withdrawals.
Intention To Treat Analysis Unclear risk Method of analysis not stated.
Cointerventions Constant Unclear risk Drug therapy not described.
Blinded Assessors Low risk Assessors blinded except for functional reach mea-
surement.
Stozek 2003
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated as outpatients for 56 hours over 4 weeks.
Assessed at baseline, immediately and 1 month after treatment
Not stated whether assessors were blinded or not.
Participants 30 participants in the exercise group and 31 participants in the control group. No dropouts described
Participants’ mean age 64 years (exercise), 67 years (control); male/female 13/17 (exercise), 16/15
(control); Hoehn and Yahr 2.3 for both groups. Mean duration of PD 4.6 years (exercise), 4.3 years
(control)
Inclusion criteria: idiopathic Parkinson’s disease diagnosed by a neurologist, disease stage based on the
Hoehn and Yahr scale 1.5 beginning of 3, stable pharmacological treatment for at least the last 3
months, age 35 to 85, no other neurological disease or seriousmovement disorders, no contraindications
for physical exercise, participants written consent to participate in the study
Interventions Exercise: complex rehabilitation for 2 hours twice daily for first 2 weeks, then once a day three times
a week for 2 weeks, for a total of 28 sessions. Sensory reinforcements were used during all exercises:
verbal, visual, auditory, extero- and proprioceptive stimulation. Complex rehabilitation consisted of
relaxation and breathing exercises, exercises increasing the range of movement, functional exercises,
exercises for posture, balance, gait, music-dance exercises, mimic exercises of facial muscle and tongue,
articulation and voice exercises, group therapy, and patient education
Control: without rehabilitation.
It was not stated whether drug therapy was stable throughout the trial
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Stozek 2003 (Continued)
Outcomes Functional reach test.
Tinetti’s Balance Performance Oriented Mobility Assessment.
Static and dynamic balance.
Timed Up and Go.
10-m walk.
Locomotion test.
360° turn.
All assessments were carried out during one day in the morning when participants were in the ’on’
phase
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method Unclear risk Randomisation method was not stated.
Concealment of Allocation Unclear risk Randomisation method was not stated.
Similarity at Baseline Low risk
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Unclear risk It was not stated whether drug therapy was stable
throughout trial
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Taheri 2011
Methods Parallel group design.
Method: randomisation method not stated.
Method of analysis not stated.
Treated for 40 hours over 10 weeks.
Assessed before and after treatment period.
Not stated whether assessors were blinded.
Participants 12 participants in the physical therapy group and 12 in the control group. No dropouts described
Baseline characteristics not stated.
Inclusion criteria: idiopathic Parkinson’s disease, able to carry out activities of daily living indepen-
dently, not part of any sports or physiotherapy treatment while participating in study, Hoehn & Yahr
stage III. Exclusion criteria: secondary drawbacks (e.g. heart disease, arthritis, cognitive problems, not
participating in experiments regularly)
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Taheri 2011 (Continued)
Interventions Physical therapy program: emphasis on tensional and supple exercises, chosen fromPito deOto physical
therapy and Donaron Rehabilitation centre, 5-minute warm-up of walking and exercises, 50 minutes
of stretching and exercise, and 50minute cool-down
Control group: no exercise.
Both groups used the same doses of medications and were kept on the same medications throughout
the trial
Outcomes Berg balance scale.
Tinetti balance scale.
Notes Translated from Farsi.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk Eligibility criteria described.
Randomisation Method Unclear risk Method not stated.
Concealment of Allocation Unclear risk Randomisation method not stated.
Similarity at Baseline Unclear risk Baseline characteristics not stated.
Withdrawals Described Unclear risk Withdrawals not described.
Intention To Treat Analysis Unclear risk Analysis method not stated.
Cointerventions Constant Low risk No medication changes occurred during trial pe-
riod.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Talakad 2011
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not described.
Treated for 8 hours over 4 weeks.
Assessed at baseline and after 4 weeks of intervention.
Not stated whether assessors were blinded.
Participants 60 participants were randomised into this trial. Dropouts were not described
Baseline characteristics of participants were not stated.
Eligibility criteria not stated.
Interventions Conventional gait training (CGT).
Partial weight supported treadmill training: 20% unweighting
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Talakad 2011 (Continued)
Control: no specific intervention.
Drug therapy not described.
Outcomes Dynamic posturography.
UPDRS.
Beat-to-beat finger blood pressure.
Notes Abstract only.
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Unclear risk Eligibility criteria not stated.
Randomisation Method Unclear risk Method of randomisation not stated.
Concealment of Allocation Unclear risk Method of randomisation not stated.
Similarity at Baseline Unclear risk Baseline characteristics not stated.
Withdrawals Described Unclear risk Dropouts not described.
Intention To Treat Analysis Unclear risk Method of analysis not stated.
Cointerventions Constant Unclear risk Drug therapy not described.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
Thaut 1996
Methods Parallel group design.
Randomised by a ’random draw,’ but concealment of allocation unclear
Method of analysis not described.
Treated at home or in the community for 10.5 hours over 3 weeks
Assessed in the laboratory at baseline and immediately after treatment
Not stated whether the assessors were blinded.
Participants 15 participants in the cueing group, 11 participants in the exercise group, and 11 participants in the
control group. No dropouts described
Participants’ mean age, 69 (cueing), 74 (exercise), 71 (control); male/female 10/5 (cueing) 8/3 (exercise)
, 8/3 (control); Hoehn and Yahr 2.4 (cueing), 2.5 (exercise), 2.6 (control). Mean duration of PD 7.2
years (cueing), 5.4 years (exercise), 8.5 years (control)
Inclusion criteria: idiopathic Parkinson’s disease with significant gait deficits regarding speed, stride
length, and cadence, but able to walk without physical assistance. No exclusion criteria
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Thaut 1996 (Continued)
Interventions Cueing: Exercised for 30 minutes daily according to a prescribed program using rhythmic auditory
stimulation (RAS). The RAS program consisted of walking on a flat surface, stair stepping, and stop-
and-go exercises to rhythmically accentuated music at three different tempos. The tempos were labelled
’normal,’ ’quick,’ and ’fast.’
Exercise (self-paced therapy, SPT): performed their 300minute daily walking sessions without RAS,
following the same training protocol and training exercises for the same length of time. Walking was
divided equally into walking at normal pace, quick pace, and fast pace
Control: no treatment.
Drugs stable during therapy.
Outcomes Walk speed.
Stride cadence.
Stride length.
EMG analysis on leg muscles.
Footfall pattern.
All testing done 90 to 120 minutes after first medication intake in morning
Notes 3 arms to the trial: RAS, SPT, and no treatment. SPT vs RAS are examined in ’A comparison of
physiotherapy techniques for participants with Parkinson’s disease.’ Cochrane review
Risk of bias
Bias Authors’ judgement Support for judgement
Eligibility Criteria Low risk
Randomisation Method High risk Random draw.
Concealment of Allocation Unclear risk No information provided to allow assessment.
Similarity at Baseline Low risk
Withdrawals Described Unclear risk No dropouts described.
Intention To Treat Analysis Unclear risk Method of analysis not described.
Cointerventions Constant Low risk Medication remained stable throughout study.
Blinded Assessors Unclear risk Not stated whether assessors were blinded.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergen 2002 No outcome measures relevant to our review.
Blackinton 2002 Initially identified as a suitable study for inclusion but was excluded because of the number of dropouts (47%;
final number of participants analysed, n=8), which left the two groups unmatched by age and duration of
Parkinson’s disease
Bridgewater 1997 Although this trial was designed as an RCT, after discussion with the authors it was discovered that themethod
of randomisation was compromised. ’In order of response to advertising, subjects were allocated alternately
to group A (period of exercise, then no exercise) and group B (control, then complimentary exercise classes)
.’ Although alternate allocation is an acceptable method of randomisation, the authors went on to change
participants from group A to B if their personal circumstances dictated that they would be unavailable for the
physiotherapy (e.g. if they were leaving the state on holiday).We feel that this compromised the randomisation
procedure, and therefore excluded the trial
Byl 2009 After email correspondence with the author, this trial was found out not to be randomised
Chouza 2011 Whole body vibration technique not usually used by Physiotherapists
Christofoletti 2010 Excluded as although the abstract for the study states ’randomised controlled trial,’ after translation of the
full paper, the study did not appear to be randomised; ’allocated to groups on convenience basis, following
availability of participants at treatment site.’ Attempted to contact author to clarify randomisation method
but were unsuccessful
Cianci 2010 Excluded as confounded because of use of rolling walker.
Comella 1994 The study did not report outcomes for the first assessment period and therefore has been excluded to prevent
any bias of carryover or order effects
Forkink 1996 No outcome measures relevant to our review.
Formisano 1992 Although this trial was controlled, the authors did not state that the allocation of participants into the two
groups was random
Gibberd 1981 The study did not report outcomes for the first assessment period and therefore has been excluded to prevent
any bias of carryover or order effects
Guo 2009 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Haas 2006 Excluded as the study was a randomised cross-over over a couple of hours
Hurwitz 1989 No outcome measures relevant to our review.
Kapur 2011 Whole-body vibration technique not usually used by physiotherapists
83Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Katsikitis 1996 No outcome measures relevant to our review.
Kaut 2011 Whole-body vibration technique not usually used by physiotherapists
King 2009 Excluded as the study was a randomised cross-over on the same day
Knobl 2011 Not properly randomised, placed in groups.
Koc 2012 No patient numbers, methods, or data available; unable to make contact with authors
Lee 2012 Upon discussion with the authors, it was discovered that the method of randomisation was compromised as
all patients in the control arm received delayed treatment and were added into the experimental group
Patti 1996 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Pohl 2003 Randomised multiple intervention cross-over, over 4 consecutive days. Randomisation was of the sequence
of the interventions, therefore not RCT
Rochester 2011 Excluded, as the study was a randomised cross-over over a couple of hours
Sage 2009b Upon contacting the author, it was found that the study was not properly randomised
Stallibrass 2002 The method of therapy used Alexander Technique is not used by physiotherapists. Therefore this trial
was excluded
Tickle-Degnen 2010 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Van Gerpen 2010 Excluded as confounded because of the use of a four-wheeled walker
Wade 2003 Multidisciplinary rehabilitation trail. Percentage component of physiotherapy was not specified, therefore
unable to differentiate the contribution of physiotherapy to any change in the outcome measures
Wells 1999 Although not stated in the text, upon personal communication with the author, this trial was determined
to be an RCT. However the method of therapy used osteopathic manipulative treatment is not used by
physiotherapists. Therefore this trial was excluded
Yen 2011 No outcome measures relevant to our review.
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Characteristics of ongoing studies [ordered by study ID]
Canning 2009
Trial name or title Exercise therapy for prevention of falls in people with Parkinson’s disease: a randomised controlled trial
Methods Parallel group design.
Randomisation was stratified by falls history (0-10 falls in the previous 12 months/more than 10 falls in the
previous 12 months) using a computer-generated random number schedule with variable block sizes of 2 to
6. Randomisation was performed centrally by an investigator not involved in recruitment or assessments
Assessors were blinded.
Participants 230 participants.
Inclusion criteria: diagnosis of Idiopathic Parkinson’s disease. Adapted to their current antiparkinsonian
medication for at least 2 weeks. Aged 40 years or over. Able to walk independently (with or without walking
aid). Have a history of falls (at least one fall in the previous 12 months) or are at risk of falls
Exclusion criteria: Mini-Mental State Examination score of < 24. Suffer from unstable cardiovascular disease
or other uncontrolled chronic conditions that would interfere with the safety and conduct of the training and
testing protocol or interpretation of the results
Interventions Exercise: 40- to 60-minute program of home-based balance and leg strength exercises three times a week for 6
months. Participants can choose to participate in a once-a-month exercise class (for 6 months) conducted by a
physiotherapist in association with the local Parkinson’s NSW/ACT Support Group or hospital. Participants
will be provided with a booklet containing safety precautions, instructions, and photographs of exercises for
use in exercise sessions at home, as well as information sheets detailing strategies for managing freezing. In
addition, they will be provided with a logbook for recording exercises completed and any adverse effects of
exercise. Participants will also receive standardised falls prevention advice and will be provided with a falls
diary for recording falls
Control: will have standardised falls prevention advice and will be provided with a falls diary for recording
falls
Outcomes Falls diary*.
Parkinson’s Disease Falls Risk Score.
Maximal muscle strength, knee extension (quadriceps).
Step test component from the Berg Balance Scale.
Short Physical Performance Battery.
Freezing of Gait Questionnaire.
SF12v2T M health survey.
Falls Efficacy Scale International Questionnaire.
Habitual Physical Activity Questionnaire.
PDQ-39.
Positive and Negative Affect Schedule (PANAS).
Total cost*.
Tested at baseline and at the end of the 6-month intervention period. *Data collected monthly
Starting date 01/05/2008.
Contact information Dr Colleen Canning (c.canning@usyd.edu.au).
Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney
Notes Australian New Zealand Clinical Trials Registry Number: ACTRN12608000303347
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Ledger 2008
Trial name or title A randomised controlled trial (RCT) to evaluate use of auditory cueing device’s (IACDs) on freezing and gait
in people with Parkinson’s disease (PD)
Methods Randomly assigned using sealed, computer-generated random numbers
Participants 47 participants.
Inclusion criteria: Parkinson’s disease, medically stable, willing to give informed consent, freeze at least once
per week (minimum score of 2 on item 3 of the FOGQ) for at least 2 seconds (minimum score of 1 on item
4 of FOGQ), MMSE score greater than 24
Exclusion criteria: attending physiotherapy at time of recruitment, unwilling to give informed consent, not
medically stable, cognitive impairment (MMSE score less than 24), acute comorbidity that prevents mobility
Interventions Cross-over trial.
Cueing: iPod containing an auditory cue in the form of a continuous metronome beat, individualised to
participants’ walking frequency (less than 10%). Participants instructed to listen to cueing when performing
any mobility-related tasks for 8 days
Control: iPod shuffle with no music or metronome beat for 8 days
Outcomes Freezing of Gait Questionnaire.
Timed Up and Go Test.
Modified Falls Efficacy Scale.
10-Metre Walk Test.
Tested on days 8, 15, and 23 and at 3 months.
Starting date Study not yet open for recruitment.
Contact information Dr Emma K Stokes (estokes@tcd.ie).
Notes On days 1-8 of the trial, both groups given an iPod with some music on it to allow all participants to become
familiar with the device. They will be instructed to use the device only when sitting at home, and that the
device should not be turned on when walking or performing any mobility-related or daily tasks
NCT00727467.
Martin 2009
Trial name or title Home-based rehabilitation to reduce falls in people with Parkinson’s disease (PD): a randomised controlled
trial
Methods Parallel group design.
Participants 180 participants.
Inclusion criteria: idiopathic Parkinson’s disease, living in the community, Hoehn and Yahr stages 1 to 4
Exclusion criteria: suffer from cardiopulmonary, musculoskeletal, endocrine, or other medical condition that
prevents safe participation in a home exercise program; participant or their carer/family are unwilling to have
therapy and assessments in the home, are unable to communicate in English, have a dementia score MMSE
score < 24, and unable to provide informed consent
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Martin 2009 (Continued)
Interventions Active intervention: 6-week individualised home-based rehabilitation program comprising a once-weekly
1-hour program delivered by a trained therapist, together with a once-weekly 1-hour self-directed exercise
program. The intervention is designed to provide participants with an integrated ’package’ of evidence-based
therapy, including movement strategy training, strengthening, and falls education
Active control: 6-week individualised home-based ’life skills’ program comprising a once-weekly 1-hour
program delivered by a trained therapist, together with a once-weekly self-directed life skills home program.
The active control is designed to provide education on taking medication, managing stress, driving, and other
daily activities and will include content related to falls, physical exercise, and gait rehabilitation
Outcomes Fall frequency and injuries*.
UPDRS total and motor.
PDQ-39.
EuroQOL*.
Tested at baseline, at 6 weeks, and at 12 months. *12 months only
Starting date 01/08/2008
Contact information Dr C Martin (cmartin@unimelb.edu.au).
Centre for Health Exercise and Sports Medicine, School of Physiotherapy, The University of Melbourne
Notes ACTRN12608000390381.
Schenkman 2009
Trial name or title Exercise, physical function, and Parkinson’s disease.
Methods 3-Arm parallel group design.
Participants
Interventions Exercise 1: general endurance training.
Exercise 2: PD-specific flexibility and functional training.
Control: usual care based on a booklet based on the American Parkinson Foundation
Outcomes Continuous-Scale Physical Functional Performance Test.
Functional Reach.
O2 consumption at a set walking speed.
Assessed at baseline, after treatment, and at 10 and 16 months
Starting date 11/04/2003.
Contact information Nancy Shinowara (shinowara@nih.gov).
Notes Information obtained from CRISP/RePORT database.
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Schenkman 2012
Trial name or title Endurance exercise.
Methods Parallel group design.
Method of randomisation not stated.
Method of analysis not stated.
Treatment schedule not stated.
Assessment intervals not stated.
Assessors were blinded.
Participants Number of participants, group allocation, and dropouts were not described
Baseline characteristics were not stated.
Eligibility criteria were not stated.
Interventions Moderate exercise.
Vigorous exercise.
Drug therapy not described.
Outcomes Adherence to exercise.
UPDRS Motor.
Starting date January 2012.
Contact information Margaret Schenkman, University of Colarado, Denver.
Notes Information obtained from ClinicalTrials.gov.
Woo 2010
Trial name or title The effectiveness of physiotherapy interventions for patients with Parkinson’s disease
Methods 2-Arm parallel group design.
Participants Estimated enrolment: 112.
Inclusion criteria: stable medication usage. Hoehn and Yahr stage II to IV. At least 1 score of 2 or more for
at least 1 limb of the tremor, rigidity, or bradykinesia item of the Unified Parkinson’s Disease Rating Scale
(UPDRS). Able to walk independently. No severe cognitive impairments (Mini-Mental State Examination
Chinese Cantonese version score greater than 24)
Exclusion criteria: other severe neurological, cardiopulmonary, or orthopedic disorders. Having participated
in a physiotherapy or rehabilitation program in previous 2 months
Interventions Physiotherapy intervention: physiotherapy interventions including strengthening exercise, balance training,
gait training with visual cue, gait training with treadmill
Education intervention: education classes.
Outcomes Movement Disorder Society Unified Parkinson’s Disease Rating Scale
Levodopa equivalent daily dosage (LEDD).
Timed Up and Go Test.
Activities-Specific Balance Confidence Scale (Chinese version)
Parkinson’s Disease Questionnaire (standard Chinese version)
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Woo 2010 (Continued)
Number of injurious falls.
Starting date 03/2010.
Contact information CW Woo (woocx@ha.org.hk).
Notes NCT01076712.
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D A T A A N D A N A L Y S E S
Comparison 1. Gait Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 2 or 6 Minute Walk Test (m) 6 242 Mean Difference (IV, Fixed, 95% CI) 13.37 [0.55, 26.20]
1.1 Exercise v Control 3 98 Mean Difference (IV, Fixed, 95% CI) 10.14 [-5.70, 25.97]
1.2 Treadmill v Control 1 18 Mean Difference (IV, Fixed, 95% CI) -4.80 [-36.63, 27.
03]
1.3 Dance v Control 2 100 Mean Difference (IV, Fixed, 95% CI) 38.94 [-3.18, 81.06]
1.4 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) 43.6 [0.71, 86.49]
2 10 or 20m Walk Test (s) 4 169 Mean Difference (IV, Fixed, 95% CI) 0.40 [0.00, 0.80]
2.1 Exercise v Control 3 145 Mean Difference (IV, Fixed, 95% CI) 0.41 [0.02, 0.81]
2.2 Treadmill v Control 1 24 Mean Difference (IV, Fixed, 95% CI) -0.8 [-4.41, 2.81]
3 Speed (m/s) 15 814 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.02, 0.06]
3.1 General Physiotherapy v
Control
3 137 Mean Difference (IV, Fixed, 95% CI) 0.09 [0.01, 0.17]
3.2 Exercise v Control 5 248 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.01, 0.06]
3.3 Treadmill v Control 3 56 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.04, 0.12]
3.4 Cueing v Control 6 299 Mean Difference (IV, Fixed, 95% CI) 0.05 [0.02, 0.09]
3.5 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.16, 0.22]
3.6 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.22, 0.04]
4 Cadence (steps/min) 7 350 Mean Difference (IV, Fixed, 95% CI) -1.57 [-3.81, 0.67]
4.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -2.40 [-11.12, 6.32]
4.2 Exercise v Control 2 68 Mean Difference (IV, Fixed, 95% CI) -1.70 [-6.30, 2.90]
4.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) -0.04 [-6.48, 6.39]
4.4 Cueing v Control 4 224 Mean Difference (IV, Fixed, 95% CI) -1.74 [-4.70, 1.21]
5 Stride Length (m) 6 225 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.02, 0.08]
5.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.19, 0.15]
5.2 Exercise v Control 1 22 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.03, 0.37]
5.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.07, 0.14]
5.4 Cueing v Control 3 71 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.02, 0.17]
5.5 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.10, 0.24]
5.6 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.1 [-0.23, 0.03]
6 Step Length (m) 5 383 Mean Difference (IV, Fixed, 95% CI) 0.02 [-4.67, 0.04]
6.1 General Physiotherapy v
Control
1 20 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.10, 0.06]
6.2 Exercise v Control 2 148 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.02, 0.04]
6.3 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.08, 0.10]
6.4 Cueing v Control 2 195 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.01, 0.07]
7 Freezing of Gait Questionnaire 4 298 Mean Difference (IV, Fixed, 95% CI) -1.41 [-2.63, -0.19]
7.1 Exercise v Control 1 45 Mean Difference (IV, Fixed, 95% CI) -2.40 [-5.76, 0.96]
7.2 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) -0.87 [-2.43, 0.69]
7.3 Dance v Control 2 100 Mean Difference (IV, Fixed, 95% CI) -2.21 [-4.63, 0.22]
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Comparison 2. Functional Mobility and Balance Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Timed Up & Go (s) 9 639 Mean Difference (IV, Fixed, 95% CI) -0.63 [-1.05, -0.21]
1.1 Exercise v Control 6 370 Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.88, 0.45]
1.2 Cueing v Control 2 195 Mean Difference (IV, Fixed, 95% CI) -0.77 [-2.05, 0.52]
1.3 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -3.10 [-7.76, 1.56]
1.4 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) -0.9 [-1.50, -0.30]
2 Functional Reach (cm) 4 393 Mean Difference (IV, Fixed, 95% CI) 2.16 [0.89, 3.43]
2.1 Exercise v Control 3 240 Mean Difference (IV, Fixed, 95% CI) 2.46 [0.94, 3.97]
2.2 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) 1.46 [-0.88, 3.80]
3 Berg Balance Scale 5 385 Mean Difference (IV, Fixed, 95% CI) 3.71 [2.30, 5.11]
3.1 Exercise v Control 3 280 Mean Difference (IV, Fixed, 95% CI) 2.79 [0.50, 5.08]
3.2 Treadmill v Control 1 31 Mean Difference (IV, Fixed, 95% CI) 8.29 [1.07, 15.51]
3.3 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) 5.15 [0.42, 9.88]
3.4 Martial Arts v Control 1 26 Mean Difference (IV, Fixed, 95% CI) 3.80 [1.81, 5.79]
4 Activity Specific Balance
Confidence
3 66 Mean Difference (IV, Fixed, 95% CI) 2.40 [-2.78, 7.57]
4.1 Exercise v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 3.63 [-2.09, 9.36]
4.2 Cueing v Control 1 28 Mean Difference (IV, Fixed, 95% CI) -3.1 [-15.18, 8.98]
Comparison 3. Falls
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Falls Efficacy Scale 4 353 Mean Difference (IV, Fixed, 95% CI) -1.91 [-4.76, 0.94]
1.1 Exercise v Control 2 169 Mean Difference (IV, Fixed, 95% CI) -2.35 [-5.38, 0.69]
1.2 Treadmill v Control 1 31 Mean Difference (IV, Fixed, 95% CI) -14.67 [-39.11, 9.
77]
1.3 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) 3.32 [-5.38, 12.02]
Comparison 4. Clinician-Rated Disability
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 UPDRS - Total 3 207 Mean Difference (IV, Fixed, 95% CI) -6.15 [-8.57, -3.73]
1.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -4.84 [-7.63, -2.04]
1.2 Exercise v Control 1 102 Mean Difference (IV, Fixed, 95% CI) -12.90 [-18.30, -7.
50]
1.3 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 1.1 [-9.60, 11.80]
2 UPDRS - Mental 2 105 Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.98, 0.09]
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2.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -0.47 [-1.05, 0.11]
2.2 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) -0.3 [-1.64, 1.04]
3 UPDRS - ADL 3 157 Mean Difference (IV, Fixed, 95% CI) -1.36 [-2.41, -0.30]
3.1 General Physiotherapy v
Control
2 85 Mean Difference (IV, Fixed, 95% CI) -1.62 [-2.77, -0.47]
3.2 Treadmill v Control 1 20 Mean Difference (IV, Fixed, 95% CI) 1.50 [-1.81, 4.81]
3.3 Dance v Control 1 52 Mean Difference (IV, Fixed, 95% CI) -2.50 [-6.83, 1.83]
4 UPDRS - Motor 12 593 Mean Difference (IV, Fixed, 95% CI) -5.01 [-6.30, -3.72]
4.1 General Physiotherapy v
Control
3 137 Mean Difference (IV, Fixed, 95% CI) -3.08 [-5.24, -0.92]
4.2 Exercise v Control 2 148 Mean Difference (IV, Fixed, 95% CI) -10.02 [-12.81, -7.
23]
4.3 Treadmill v Control 2 38 Mean Difference (IV, Fixed, 95% CI) 0.05 [-3.93, 4.03]
4.4 Cueing v Control 3 92 Mean Difference (IV, Fixed, 95% CI) -3.15 [-6.68, 0.37]
4.5 Dance v Control 2 100 Mean Difference (IV, Fixed, 95% CI) -8.48 [-12.76, -4.19]
4.6 Martial Arts v Control 2 78 Mean Difference (IV, Fixed, 95% CI) -5.82 [-9.79, -1.85]
Comparison 5. Patient-Rated Quality of Life
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PDQ-39 Summary Index 7 405 Mean Difference (IV, Fixed, 95% CI) -0.38 [-2.58, 1.81]
1.1 General Physiotherapy v
Control
1 52 Mean Difference (IV, Fixed, 95% CI) 0.68 [-6.84, 8.20]
1.2 Exercise v Control 3 104 Mean Difference (IV, Fixed, 95% CI) 0.32 [-3.83, 4.48]
1.3 Treadmill v Control 1 18 Mean Difference (IV, Fixed, 95% CI) -0.7 [-7.69, 6.29]
1.4 Cueing v Control 1 153 Mean Difference (IV, Fixed, 95% CI) -1.58 [-5.45, 2.29]
1.5 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -2.34 [-8.83, 4.15]
1.6 Martial Arts v Control 1 30 Mean Difference (IV, Fixed, 95% CI) 3.05 [-3.81, 9.91]
2 PDQ-39 Mobility 2 105 Mean Difference (IV, Fixed, 95% CI) -1.43 [-8.03, 5.18]
2.1 General Physiotherapy v
Control
1 27 Mean Difference (IV, Fixed, 95% CI) 6.23 [-3.85, 16.31]
2.2 Dance v Control 1 48 Mean Difference (IV, Fixed, 95% CI) -10.41 [-22.50, 1.
68]
2.3 Martial Arts v Control 1 30 Mean Difference (IV, Fixed, 95% CI) -3.65 [-16.30, 9.00]
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Analysis 1.1. Comparison 1 Gait Outcomes, Outcome 1 2 or 6 Minute Walk Test (m).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 1 2 or 6 Minute Walk Test (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Meek 2010 19 6.1 (32.5) 18 0.7 (38.7) 30.8 % 5.40 [ -17.69, 28.49 ]
Schenkman 1998 23 15.4 (35.7) 23 1.9 (42.5) 32.0 % 13.50 [ -9.18, 36.18 ]
Schilling 2008 8 49.2 (76.6) 7 25.1 (75.6) 2.8 % 24.10 [ -53.06, 101.26 ]
Subtotal (95% CI) 50 48 65.6 % 10.14 [ -5.70, 25.97 ]
Heterogeneity: Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Treadmill v Control
Canning 2008 9 13.3 (28.8) 9 18.1 (39.3) 16.2 % -4.80 [ -36.63, 27.03 ]
Subtotal (95% CI) 9 9 16.2 % -4.80 [ -36.63, 27.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
3 Dance v Control
Duncan 2012 26 2.2 (102.9) 26 -21.6 (97) 5.6 % 23.80 [ -30.56, 78.16 ]
Hackney 2009 31 54.2 (80.2) 17 -7.5 (127) 3.7 % 61.70 [ -4.95, 128.35 ]
Subtotal (95% CI) 57 43 9.3 % 38.94 [ -3.18, 81.06 ]
Heterogeneity: Chi2 = 0.75, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.070)
4 Martial Arts v Control
Hackney 2009 13 44.4 (65.9) 13 0.8 (43.4) 8.9 % 43.60 [ 0.71, 86.49 ]
Subtotal (95% CI) 13 13 8.9 % 43.60 [ 0.71, 86.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.046)
Total (95% CI) 129 113 100.0 % 13.37 [ 0.55, 26.20 ]
Heterogeneity: Chi2 = 5.85, df = 6 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 4.74, df = 3 (P = 0.19), I2 =37%
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Analysis 1.2. Comparison 1 Gait Outcomes, Outcome 2 10 or 20mWalk Test (s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 2 10 or 20m Walk Test (s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Meek 2010 20 0 (2.2) 18 -0.7 (3.8) 3.9 % 0.70 [ -1.30, 2.70 ]
Schenkman 1998 23 0.1 (0.2) 23 -0.4 (1) 90.3 % 0.50 [ 0.08, 0.92 ]
Stozek 2003 30 -1.3 (1.8) 31 0.2 (4.9) 4.6 % -1.50 [ -3.34, 0.34 ]
Subtotal (95% CI) 73 72 98.8 % 0.41 [ 0.02, 0.81 ]
Heterogeneity: Chi2 = 4.39, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 2.04 (P = 0.042)
2 Treadmill v Control
Kurtais 2008 12 -2.5 (5.2) 12 -1.7 (3.7) 1.2 % -0.80 [ -4.41, 2.81 ]
Subtotal (95% CI) 12 12 1.2 % -0.80 [ -4.41, 2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Total (95% CI) 85 84 100.0 % 0.40 [ 0.00, 0.80 ]
Heterogeneity: Chi2 = 4.82, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.43, df = 1 (P = 0.51), I2 =0.0%
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Analysis 1.3. Comparison 1 Gait Outcomes, Outcome 3 Speed (m/s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 3 Speed (m/s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 0.13 (0.36) 26 0.1 (0.3) 1.5 % 0.03 [ -0.15, 0.21 ]
Ellis 2005 32 0.16 (0.22) 33 0.01 (0.21) 4.5 % 0.15 [ 0.05, 0.25 ]
Fisher 2008 10 0.02 (0.18) 10 0.02 (0.17) 2.1 % 0.0 [ -0.15, 0.15 ]
Subtotal (95% CI) 68 69 8.0 % 0.09 [ 0.01, 0.17 ]
Heterogeneity: Chi2 = 3.01, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 2.23 (P = 0.025)
2 Exercise v Control
Allen 2010 21 0.02 (0.27) 24 0.02 (0.29) 1.8 % 0.0 [ -0.16, 0.16 ]
Boehm 2011 50 0.01 (0.24) 52 0 (0.23) 5.8 % 0.01 [ -0.08, 0.10 ]
Mak 2008 19 0.02 (0.08) 14 0 (0.06) 21.4 % 0.02 [ -0.03, 0.07 ]
Sage 2009a 31 0.06 (0.2) 15 0 (0.22) 2.8 % 0.06 [ -0.07, 0.20 ]
Thaut 1996 11 0.07 (0.18) 11 -0.05 (0.27) 1.3 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 132 116 33.2 % 0.03 [ -0.01, 0.06 ]
Heterogeneity: Chi2 = 1.49, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 Treadmill v Control
Canning 2008 9 0.09 (0.12) 9 0.06 (0.09) 5.1 % 0.03 [ -0.07, 0.13 ]
Fisher 2008 10 0.06 (0.2) 10 0.02 (0.17) 1.8 % 0.04 [ -0.12, 0.20 ]
Protas 2005 9 0.17 (0.35) 9 0.01 (0.23) 0.7 % 0.16 [ -0.11, 0.43 ]
Subtotal (95% CI) 28 28 7.6 % 0.04 [ -0.04, 0.12 ]
Heterogeneity: Chi2 = 0.77, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.29)
4 Cueing v Control
Almeida 2012 28 0.06 (0.19) 14 0.01 (0.27) 2.0 % 0.05 [ -0.11, 0.21 ]
de Bruin 2010a 11 0.03 (0.22) 11 -0.02 (0.17) 1.8 % 0.05 [ -0.11, 0.21 ]
Haase 2011 17 -0.05 (0.26) 6 0.05 (0.2) 1.2 % -0.10 [ -0.30, 0.10 ]
Mak 2008 19 0.05 (0.06) 14 0 (0.06) 28.4 % 0.05 [ 0.01, 0.09 ]
Nieuwboer 2007 76 0.08 (0.16) 77 0.02 (0.23) 12.4 % 0.06 [ 0.00, 0.12 ]
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Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Thaut 1996 15 0.16 (0.22) 11 -0.05 (0.27) 1.3 % 0.21 [ 0.02, 0.40 ]
Subtotal (95% CI) 166 133 47.0 % 0.05 [ 0.02, 0.09 ]
Heterogeneity: Chi2 = 4.71, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.24 (P = 0.0012)
5 Dance v Control
Hackney 2009 31 0.05 (0.2) 17 0.02 (0.38) 1.3 % 0.03 [ -0.16, 0.22 ]
Subtotal (95% CI) 31 17 1.3 % 0.03 [ -0.16, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
6 Martial Arts v Control
Hackney 2009 13 0.01 (0.21) 13 0.1 (0.11) 2.9 % -0.09 [ -0.22, 0.04 ]
Subtotal (95% CI) 13 13 2.9 % -0.09 [ -0.22, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 438 376 100.0 % 0.04 [ 0.02, 0.06 ]
Heterogeneity: Chi2 = 16.63, df = 18 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.69 (P = 0.00022)
Test for subgroup differences: Chi2 = 6.64, df = 5 (P = 0.25), I2 =25%
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Analysis 1.4. Comparison 1 Gait Outcomes, Outcome 4 Cadence (steps/min).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 4 Cadence (steps/min)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 -1.6 (10.9) 10 0.8 (8.9) 6.6 % -2.40 [ -11.12, 6.32 ]
Subtotal (95% CI) 10 10 6.6 % -2.40 [ -11.12, 6.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Exercise v Control
Sage 2009a 31 1.1 (9.2) 15 0 (8.7) 16.8 % 1.10 [ -4.37, 6.57 ]
Thaut 1996 11 -0.4 (8) 11 8.1 (12) 6.9 % -8.50 [ -17.02, 0.02 ]
Subtotal (95% CI) 42 26 23.8 % -1.70 [ -6.30, 2.90 ]
Heterogeneity: Chi2 = 3.45, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Treadmill v Control
Fisher 2008 10 0.2 (9.6) 10 0.8 (8.9) 7.6 % -0.60 [ -8.71, 7.51 ]
Protas 2005 9 7.5 (7.7) 9 6.6 (14.2) 4.5 % 0.90 [ -9.65, 11.45 ]
Subtotal (95% CI) 19 19 12.2 % -0.04 [ -6.48, 6.39 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
4 Cueing v Control
de Bruin 2010a 11 2 (7.9) 11 1 (12.5) 6.6 % 1.00 [ -7.74, 9.74 ]
Haase 2011 17 2.05 (14.78) 6 0.5 (9.78) 4.5 % 1.55 [ -8.97, 12.07 ]
Nieuwboer 2007 76 -0.4 (10.2) 77 2.5 (11.9) 40.8 % -2.90 [ -6.41, 0.61 ]
Thaut 1996 15 8.9 (12.6) 11 8.1 (11.96) 5.5 % 0.80 [ -8.72, 10.32 ]
Subtotal (95% CI) 119 105 57.5 % -1.74 [ -4.70, 1.21 ]
Heterogeneity: Chi2 = 1.45, df = 3 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
Total (95% CI) 190 160 100.0 % -1.57 [ -3.81, 0.67 ]
Heterogeneity: Chi2 = 5.22, df = 8 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 0.27, df = 3 (P = 0.97), I2 =0.0%
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Analysis 1.5. Comparison 1 Gait Outcomes, Outcome 5 Stride Length (m).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 5 Stride Length (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 0.02 (0.15) 10 0.04 (0.23) 9.7 % -0.02 [ -0.19, 0.15 ]
Subtotal (95% CI) 10 10 9.7 % -0.02 [ -0.19, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
2 Exercise v Control
Thaut 1996 11 0.08 (0.19) 11 -0.09 (0.29) 6.7 % 0.17 [ -0.03, 0.37 ]
Subtotal (95% CI) 11 11 6.7 % 0.17 [ -0.03, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
3 Treadmill v Control
Fisher 2008 10 0.06 (0.17) 10 0.04 (0.23) 8.9 % 0.02 [ -0.16, 0.20 ]
Protas 2005 9 0.04 (0.15) 9 0 (0.13) 16.6 % 0.04 [ -0.09, 0.17 ]
Subtotal (95% CI) 19 19 25.6 % 0.03 [ -0.07, 0.14 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
4 Cueing v Control
de Bruin 2010a 11 0.01 (0.18) 11 -0.03 (0.14) 15.4 % 0.04 [ -0.09, 0.17 ]
Haase 2011 17 0 (0.2) 6 -0.03 (0.18) 9.4 % 0.03 [ -0.15, 0.20 ]
Thaut 1996 15 0.11 (0.18) 11 -0.09 (0.29) 7.4 % 0.20 [ 0.01, 0.39 ]
Subtotal (95% CI) 43 28 32.2 % 0.07 [ -0.02, 0.17 ]
Heterogeneity: Chi2 = 2.17, df = 2 (P = 0.34); I2 =8%
Test for overall effect: Z = 1.53 (P = 0.13)
5 Dance v Control
Hackney 2009 31 0.05 (0.2) 17 -0.02 (0.33) 9.5 % 0.07 [ -0.10, 0.24 ]
Subtotal (95% CI) 31 17 9.5 % 0.07 [ -0.10, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
6 Martial Arts v Control
Hackney 2009 13 -0.1 (0.23) 13 0 (0.07) 16.4 % -0.10 [ -0.23, 0.03 ]
Subtotal (95% CI) 13 13 16.4 % -0.10 [ -0.23, 0.03 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 127 98 100.0 % 0.03 [ -0.02, 0.08 ]
Heterogeneity: Chi2 = 9.14, df = 8 (P = 0.33); I2 =12%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 6.93, df = 5 (P = 0.23), I2 =28%
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Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 6 Step Length (m)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Fisher 2008 10 0.01 (0.08) 10 0.03 (0.11) 6.5 % -0.02 [ -0.10, 0.06 ]
Subtotal (95% CI) 10 10 6.5 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
2 Exercise v Control
Boehm 2011 50 0.008 (0.1) 52 0 (0.1) 30.8 % 0.00 [ -0.03, 0.04 ]
Sage 2009a 31 0.03 (0.1) 15 0 (0.11) 10.7 % 0.03 [ -0.04, 0.09 ]
Subtotal (95% CI) 81 67 41.5 % 0.01 [ -0.02, 0.04 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Treadmill v Control
Fisher 2008 10 0.04 (0.09) 10 0.03 (0.11) 6.0 % 0.01 [ -0.08, 0.10 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 10 10 6.0 % 0.01 [ -0.08, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
4 Cueing v Control
Almeida 2012 28 0.051 (0.091) 14 0.02 (0.13) 8.0 % 0.03 [ -0.04, 0.11 ]
Nieuwboer 2007 76 0.04 (0.1) 77 0 (0.12) 37.9 % 0.04 [ 0.01, 0.07 ]
Subtotal (95% CI) 104 91 46.0 % 0.04 [ 0.01, 0.07 ]
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.37 (P = 0.018)
Total (95% CI) 205 178 100.0 % 0.02 [ 0.00, 0.04 ]
Heterogeneity: Chi2 = 2.94, df = 5 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Chi2 = 2.54, df = 3 (P = 0.47), I2 =0.0%
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Analysis 1.7. Comparison 1 Gait Outcomes, Outcome 7 Freezing of Gait Questionnaire.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 1 Gait Outcomes
Outcome: 7 Freezing of Gait Questionnaire
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Allen 2010 21 -1.3 (5.5) 24 1.1 (6) 13.2 % -2.40 [ -5.76, 0.96 ]
Subtotal (95% CI) 21 24 13.2 % -2.40 [ -5.76, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
2 Cueing v Control
Nieuwboer 2007 76 -0.95 (4.74) 77 -0.08 (5.09) 61.4 % -0.87 [ -2.43, 0.69 ]
Subtotal (95% CI) 76 77 61.4 % -0.87 [ -2.43, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
3 Dance v Control
Duncan 2012 26 -0.5 (5.1) 26 1.9 (5.4) 18.3 % -2.40 [ -5.26, 0.46 ]
Hackney 2009 31 -0.5 (5) 17 1.2 (8.95) 7.0 % -1.70 [ -6.30, 2.90 ]
Subtotal (95% CI) 57 43 25.3 % -2.21 [ -4.63, 0.22 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.78 (P = 0.075)
Total (95% CI) 154 144 100.0 % -1.41 [ -2.63, -0.19 ]
Heterogeneity: Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Chi2 = 1.21, df = 2 (P = 0.55), I2 =0.0%
-10 -5 0 5 10
Favours Intervention Favours No Intervention
101Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 1 Timed Up & Go (s).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 1 Timed Up % Go (s)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Boehm 2011 50 -0.4 (5.2) 52 -0.2 (3.9) 5.5 % -0.20 [ -1.99, 1.59 ]
Goodwin 2009 61 0.13 (11.09) 62 -0.48 (13.92) 0.9 % 0.61 [ -3.83, 5.05 ]
Klassen 2007 17 -1.3 (2.5) 6 -0.2 (1.85) 4.9 % -1.10 [ -3.00, 0.80 ]
Sage 2009a 31 -0.6 (2.21) 15 0 (2.33) 8.8 % -0.60 [ -2.01, 0.81 ]
Schilling 2008 8 -0.1 (0.7) 7 -0.75 (1.2) 17.2 % 0.65 [ -0.36, 1.66 ]
Stozek 2003 30 -2.36 (2.63) 31 1.1 (7.15) 2.4 % -3.46 [ -6.15, -0.77 ]
Subtotal (95% CI) 197 173 39.7 % -0.21 [ -0.88, 0.45 ]
Heterogeneity: Chi2 = 9.66, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Cueing v Control
Almeida 2012 28 -1.45 (3.2) 14 0.1 (3.16) 4.2 % -1.55 [ -3.59, 0.49 ]
Nieuwboer 2007 76 -1.59 (4.59) 77 -1.34 (5.78) 6.4 % -0.25 [ -1.90, 1.40 ]
Subtotal (95% CI) 104 91 10.7 % -0.77 [ -2.05, 0.52 ]
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
3 Dance v Control
Hackney 2009 31 -1.1 (4.31) 17 2 (9.28) 0.8 % -3.10 [ -7.76, 1.56 ]
Subtotal (95% CI) 31 17 0.8 % -3.10 [ -7.76, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
4 Martial Arts v Control
Hackney 2009 13 -1 (0.1) 13 -0.1 (1.1) 48.8 % -0.90 [ -1.50, -0.30 ]
Subtotal (95% CI) 13 13 48.8 % -0.90 [ -1.50, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0033)
Total (95% CI) 345 294 100.0 % -0.63 [ -1.05, -0.21 ]
Heterogeneity: Chi2 = 14.00, df = 9 (P = 0.12); I2 =36%
Test for overall effect: Z = 2.95 (P = 0.0032)
Test for subgroup differences: Chi2 = 3.40, df = 3 (P = 0.33), I2 =12%
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Analysis 2.2. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 2 Functional Reach (cm).
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 2 Functional Reach (cm)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Ashburn 2007 67 0.4 (6.56) 66 -1 (7) 30.3 % 1.40 [ -0.91, 3.71 ]
Schenkman 1998 23 1.57 (4.45) 23 -0.28 (4.17) 26.0 % 1.85 [ -0.64, 4.34 ]
Stozek 2003 30 5.8 (6.01) 31 -0.03 (7.38) 14.2 % 5.83 [ 2.46, 9.20 ]
Subtotal (95% CI) 120 120 70.5 % 2.46 [ 0.94, 3.97 ]
Heterogeneity: Chi2 = 4.88, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 Cueing v Control
Nieuwboer 2007 76 1.8 (5.28) 77 0.34 (9.02) 29.5 % 1.46 [ -0.88, 3.80 ]
Subtotal (95% CI) 76 77 29.5 % 1.46 [ -0.88, 3.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Total (95% CI) 196 197 100.0 % 2.16 [ 0.89, 3.43 ]
Heterogeneity: Chi2 = 5.37, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 3.34 (P = 0.00085)
Test for subgroup differences: Chi2 = 0.49, df = 1 (P = 0.48), I2 =0.0%
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Analysis 2.3. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 3 Berg Balance Scale.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 3 Berg Balance Scale
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Ashburn 2007 67 1.5 (9.51) 66 1.6 (10.21) 17.5 % -0.10 [ -3.45, 3.25 ]
Goodwin 2009 61 3.1 (11.07) 62 -0.55 (9.88) 14.3 % 3.65 [ -0.06, 7.36 ]
Taheri 2011 12 8.4 (9.7) 12 -1.08 (3.7) 5.7 % 9.48 [ 3.61, 15.35 ]
Subtotal (95% CI) 140 140 37.6 % 2.79 [ 0.50, 5.08 ]
Heterogeneity: Chi2 = 8.04, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Treadmill v Control
Cakit 2007 21 7.09 (8.5) 10 -1.2 (10.07) 3.8 % 8.29 [ 1.07, 15.51 ]
Subtotal (95% CI) 21 10 3.8 % 8.29 [ 1.07, 15.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.024)
3 Dance v Control
Hackney 2009 31 3.95 (4.7) 17 -1.2 (9.32) 8.8 % 5.15 [ 0.42, 9.88 ]
Subtotal (95% CI) 31 17 8.8 % 5.15 [ 0.42, 9.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
4 Martial Arts v Control
Hackney 2009 13 3.3 (3) 13 -0.5 (2.1) 49.8 % 3.80 [ 1.81, 5.79 ]
Subtotal (95% CI) 13 13 49.8 % 3.80 [ 1.81, 5.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00018)
Total (95% CI) 205 180 100.0 % 3.71 [ 2.30, 5.11 ]
Heterogeneity: Chi2 = 10.57, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 5.17 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.53, df = 3 (P = 0.47), I2 =0.0%
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Analysis 2.4. Comparison 2 Functional Mobility and Balance Outcomes, Outcome 4 Activity Specific
Balance Confidence.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 2 Functional Mobility and Balance Outcomes
Outcome: 4 Activity Specific Balance Confidence
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Klassen 2007 17 1.75 (6.76) 6 -1.7 (6.87) 66.0 % 3.45 [ -2.92, 9.82 ]
Schilling 2008 8 3.3 (8.35) 7 -1.1 (15.85) 15.6 % 4.40 [ -8.69, 17.49 ]
Subtotal (95% CI) 25 13 81.6 % 3.63 [ -2.09, 9.36 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
2 Cueing v Control
Shankar 2008 14 -2.1 (16.5) 14 1 (16.1) 18.4 % -3.10 [ -15.18, 8.98 ]
Subtotal (95% CI) 14 14 18.4 % -3.10 [ -15.18, 8.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.61)
Total (95% CI) 39 27 100.0 % 2.40 [ -2.78, 7.57 ]
Heterogeneity: Chi2 = 0.99, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 0.97, df = 1 (P = 0.32), I2 =0.0%
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Analysis 3.1. Comparison 3 Falls, Outcome 1 Falls Efficacy Scale.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 3 Falls
Outcome: 1 Falls Efficacy Scale
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Exercise v Control
Allen 2010 21 -2.3 (10.6) 24 1.3 (10.56) 21.1 % -3.60 [ -9.80, 2.60 ]
Goodwin 2009 61 -0.83 (9.82) 63 1.12 (9.98) 66.8 % -1.95 [ -5.44, 1.54 ]
Subtotal (95% CI) 82 87 87.9 % -2.35 [ -5.38, 0.69 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Treadmill v Control
Cakit 2007 21 -12.27 (39.06) 10 2.4 (28.78) 1.4 % -14.67 [ -39.11, 9.77 ]
Subtotal (95% CI) 21 10 1.4 % -14.67 [ -39.11, 9.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
3 Cueing v Control
Nieuwboer 2007 76 4.48 (25.37) 77 1.16 (29.44) 10.7 % 3.32 [ -5.38, 12.02 ]
Subtotal (95% CI) 76 77 10.7 % 3.32 [ -5.38, 12.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Total (95% CI) 179 174 100.0 % -1.91 [ -4.76, 0.94 ]
Heterogeneity: Chi2 = 2.72, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 2.51, df = 2 (P = 0.28), I2 =20%
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Analysis 4.1. Comparison 4 Clinician-Rated Disability, Outcome 1 UPDRS - Total.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 1 UPDRS - Total
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -6.2 (6.2) 33 -1 (6) 66.3 % -5.20 [ -8.17, -2.23 ]
Fisher 2008 10 -5.2 (8.72) 10 -3.2 (10.1) 8.5 % -2.00 [ -10.27, 6.27 ]
Subtotal (95% CI) 42 43 74.8 % -4.84 [ -7.63, -2.04 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00069)
2 Exercise v Control
Boehm 2011 50 -7.1 (13.5) 52 5.8 (14.3) 20.1 % -12.90 [ -18.30, -7.50 ]
Subtotal (95% CI) 50 52 20.1 % -12.90 [ -18.30, -7.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.69 (P < 0.00001)
3 Treadmill v Control
Fisher 2008 10 -2.1 (14) 10 -3.2 (10.1) 5.1 % 1.10 [ -9.60, 11.80 ]
Subtotal (95% CI) 10 10 5.1 % 1.10 [ -9.60, 11.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 102 105 100.0 % -6.15 [ -8.57, -3.73 ]
Heterogeneity: Chi2 = 9.14, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 4.99 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.63, df = 2 (P = 0.01), I2 =77%
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Analysis 4.2. Comparison 4 Clinician-Rated Disability, Outcome 2 UPDRS - Mental.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 2 UPDRS - Mental
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -1.1 (1.6) 33 -0.5 (1.3) 56.7 % -0.60 [ -1.31, 0.11 ]
Fisher 2008 10 0.1 (1.37) 10 0.3 (0.91) 27.5 % -0.20 [ -1.22, 0.82 ]
Subtotal (95% CI) 42 43 84.2 % -0.47 [ -1.05, 0.11 ]
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Treadmill v Control
Fisher 2008 10 0 (1.97) 10 0.3 (0.91) 15.8 % -0.30 [ -1.64, 1.04 ]
Subtotal (95% CI) 10 10 15.8 % -0.30 [ -1.64, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
Total (95% CI) 52 53 100.0 % -0.44 [ -0.98, 0.09 ]
Heterogeneity: Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
-2 -1 0 1 2
Favours Intervention Favours No Intervention
108Physiotherapy versus placebo or no intervention in Parkinson’s disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Clinician-Rated Disability, Outcome 3 UPDRS - ADL.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 3 UPDRS - ADL
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Ellis 2005 32 -2.1 (2.8) 33 -0.3 (2.3) 71.4 % -1.80 [ -3.05, -0.55 ]
Fisher 2008 10 -1.5 (2.81) 10 -0.9 (3.9) 12.5 % -0.60 [ -3.58, 2.38 ]
Subtotal (95% CI) 42 43 83.9 % -1.62 [ -2.77, -0.47 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
2 Treadmill v Control
Fisher 2008 10 0.6 (3.64) 10 -0.9 (3.9) 10.2 % 1.50 [ -1.81, 4.81 ]
Subtotal (95% CI) 10 10 10.2 % 1.50 [ -1.81, 4.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
3 Dance v Control
Duncan 2012 26 -0.6 (7.5) 26 1.9 (8.4) 5.9 % -2.50 [ -6.83, 1.83 ]
Subtotal (95% CI) 26 26 5.9 % -2.50 [ -6.83, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 78 79 100.0 % -1.36 [ -2.41, -0.30 ]
Heterogeneity: Chi2 = 3.87, df = 3 (P = 0.28); I2 =22%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 3.34, df = 2 (P = 0.19), I2 =40%
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Analysis 4.4. Comparison 4 Clinician-Rated Disability, Outcome 4 UPDRS - Motor.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 4 Clinician-Rated Disability
Outcome: 4 UPDRS - Motor
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 -1 (7) 26 3 (6.24) 12.7 % -4.00 [ -7.60, -0.40 ]
Ellis 2005 32 -3 (6.6) 33 -0.2 (5.3) 19.5 % -2.80 [ -5.72, 0.12 ]
Fisher 2008 10 -3.8 (8.17) 10 -2.7 (8.15) 3.2 % -1.10 [ -8.25, 6.05 ]
Subtotal (95% CI) 68 69 35.5 % -3.08 [ -5.24, -0.92 ]
Heterogeneity: Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 Exercise v Control
Boehm 2011 50 -7 (8.6) 52 6 (9.5) 13.4 % -13.00 [ -16.51, -9.49 ]
Sage 2009a 31 -3.7 (6.72) 15 1.2 (7.81) 7.8 % -4.90 [ -9.51, -0.29 ]
Subtotal (95% CI) 81 67 21.2 % -10.02 [ -12.81, -7.23 ]
Heterogeneity: Chi2 = 7.51, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 7.03 (P < 0.00001)
3 Treadmill v Control
Canning 2008 9 2.4 (5.1) 9 2.3 (4.9) 7.8 % 0.10 [ -4.52, 4.72 ]
Fisher 2008 10 -2.8 (9.72) 10 -2.7 (8.15) 2.7 % -0.10 [ -7.96, 7.76 ]
Subtotal (95% CI) 19 19 10.4 % 0.05 [ -3.93, 4.03 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
4 Cueing v Control
Almeida 2012 28 1.4 (8.57) 14 2.1 (9.28) 4.9 % -0.70 [ -6.51, 5.11 ]
de Bruin 2010a 11 -5.6 (9.17) 11 -1.8 (6.53) 3.7 % -3.80 [ -10.45, 2.85 ]
Shankar 2008 14 -4 (8.29) 14 1.21 (7.75) 4.7 % -5.21 [ -11.15, 0.73 ]
Subtotal (95% CI) 53 39 13.3 % -3.15 [ -6.68, 0.37 ]
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.079)
5 Dance v Control
Duncan 2012 26 -12.7 (12.1) 26 -3 (9.4) 4.8 % -9.70 [ -15.59, -3.81 ]
Hackney 2009 31 -2.1 (10.96) 17 5 (10.33) 4.2 % -7.10 [ -13.34, -0.86 ]
Subtotal (95% CI) 57 43 9.0 % -8.48 [ -12.76, -4.19 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 3.88 (P = 0.00011)
6 Martial Arts v Control
Hackney 2009 13 -1.5 (6.6) 13 4.3 (5.6) 7.5 % -5.80 [ -10.51, -1.09 ]
Schmitz-Hubsch 2006 31 -0.32 (10.9) 21 5.54 (14.77) 3.0 % -5.86 [ -13.25, 1.53 ]
Subtotal (95% CI) 44 34 10.5 % -5.82 [ -9.79, -1.85 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0041)
Total (95% CI) 322 271 100.0 % -5.01 [ -6.30, -3.72 ]
Heterogeneity: Chi2 = 34.99, df = 13 (P = 0.00085); I2 =63%
Test for overall effect: Z = 7.63 (P < 0.00001)
Test for subgroup differences: Chi2 = 25.36, df = 5 (P = 0.00), I2 =80%
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Analysis 5.1. Comparison 5 Patient-Rated Quality of Life, Outcome 1 PDQ-39 Summary Index.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 5 Patient-Rated Quality of Life
Outcome: 1 PDQ-39 Summary Index
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Chandler 1999 26 4 (14.94) 26 3.32 (12.65) 8.5 % 0.68 [ -6.84, 8.20 ]
Subtotal (95% CI) 26 26 8.5 % 0.68 [ -6.84, 8.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
2 Exercise v Control
Allen 2010 21 -1 (14.3) 24 4.9 (26.7) 3.2 % -5.90 [ -18.21, 6.41 ]
Klassen 2007 17 0.25 (4.06) 6 -1 (5.54) 20.6 % 1.25 [ -3.58, 6.08 ]
Meek 2010 19 -2.6 (15.6) 17 -3.1 (17.42) 4.1 % 0.50 [ -10.35, 11.35 ]
Subtotal (95% CI) 57 47 27.9 % 0.32 [ -3.83, 4.48 ]
Heterogeneity: Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
3 Treadmill v Control
Canning 2008 9 0.5 (9.4) 9 1.2 (5.1) 9.9 % -0.70 [ -7.69, 6.29 ]
Subtotal (95% CI) 9 9 9.9 % -0.70 [ -7.69, 6.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
4 Cueing v Control
Nieuwboer 2007 76 -3.42 (11.08) 77 -1.84 (13.28) 32.1 % -1.58 [ -5.45, 2.29 ]
Subtotal (95% CI) 76 77 32.1 % -1.58 [ -5.45, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
5 Dance v Control
Hackney 2009 31 -3.84 (5.4) 17 -1.5 (13.05) 11.4 % -2.34 [ -8.83, 4.15 ]
Subtotal (95% CI) 31 17 11.4 % -2.34 [ -8.83, 4.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
6 Martial Arts v Control
Hackney 2009 13 1.55 (5.37) 17 -1.5 (13.05) 10.2 % 3.05 [ -3.81, 9.91 ]
Subtotal (95% CI) 13 17 10.2 % 3.05 [ -3.81, 9.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 212 193 100.0 % -0.38 [ -2.58, 1.81 ]
Heterogeneity: Chi2 = 3.00, df = 7 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 1.88, df = 5 (P = 0.87), I2 =0.0%
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Analysis 5.2. Comparison 5 Patient-Rated Quality of Life, Outcome 2 PDQ-39 Mobility.
Review: Physiotherapy versus placebo or no intervention in Parkinson’s disease
Comparison: 5 Patient-Rated Quality of Life
Outcome: 2 PDQ-39 Mobility
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 General Physiotherapy v Control
Keus 2007b 14 4.11 (14.5) 13 -2.12 (12.2) 42.9 % 6.23 [ -3.85, 16.31 ]
Subtotal (95% CI) 14 13 42.9 % 6.23 [ -3.85, 16.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.21 (P = 0.23)
2 Dance v Control
Hackney 2009 31 -5.99 (8.95) 17 4.42 (24.56) 29.8 % -10.41 [ -22.50, 1.68 ]
Subtotal (95% CI) 31 17 29.8 % -10.41 [ -22.50, 1.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.092)
3 Martial Arts v Control
Hackney 2009 13 0.77 (8.94) 17 4.42 (24.56) 27.3 % -3.65 [ -16.30, 9.00 ]
Subtotal (95% CI) 13 17 27.3 % -3.65 [ -16.30, 9.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 58 47 100.0 % -1.43 [ -8.03, 5.18 ]
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(. . . Continued)
Study or subgroup Intervention No Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 4.45, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Chi2 = 4.45, df = 2 (P = 0.11), I2 =55%
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A D D I T I O N A L T A B L E S
Table 1. Key Characteristics of Studies
Study Number
Ran-
domised
Mean
Age (yrs)
Mean
Hoehn
& Yahr
Stage
Duration
of
Disease
(yrs)
% Male Durationof
Treatment
Design Location Type of
Treatment
Allen 2010 48 67 8 54 48-72 hrs/
24 weeks
Parallel Outpatient Exercise
Almeida
2012
42 68.4 5.3 74 9 hrs/6
weeks
Parallel Outpatient Cueing
Ashburn
2007
142 72.15 3.13 8.35 61 42 hrs/6
weeks
Parallel Home Exercise
Boehm
2011
110 69.4 60 12 weeks Cross-over Exercise
Cakit
2007
54 71.8 5.58 52 30-min ses-
sions/ 8
weeks
Parallel Outpatient Treadmill
Canning
2008
20 61 9-12 hrs/6
weeks
Parallel Home Treadmill
Cerri 1994 6 15 hrs/3
weeks
Parallel Outpa-
tient/Home
Exercise
Chandler
1999
67 65.5 2.6 60 5 times/52
weeks
Parallel Home Physio
de Bruin
2010a
22 65.6 2.2 5.5 50 18 hrs/12
weeks
Parallel Outpatient Cueing
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Table 1. Key Characteristics of Studies (Continued)
de Bruin
2010b
13 3 per week/
13 weeks
Parallel Outpatient Cueing
Duncan
2012
62 70.3 2.5 56 24 hrs/2
weeks
Parallel Dance
Ellis 2005 68 64 2.4 75 18 hrs/6
weeks
Cross-over Outpatient Physio
Fisher
2008
30 62.9 1.9 1.1 63 24 sessions/
8 weeks
Parallel Outpatient Treadmill/
Physio
Ganesan
2010
20 8 hrs/4
weeks
Parallel Outpatient Treadmill
Goodwin
2009
130 71.1 2.5 8.7 57 10 weeks Parallel Outpatient Exercise
Haase
2011
26 66 52 4 mins/sin-
gle session
Parallel Cueing
Hackney
2009
75 66.6 2.1 7.7 74 20 hrs/13
weeks
Parallel Outpatient Dance/
Martial Arts
Homann
1998
15 14 units/5
weeks
Parallel Outpatient Physio
Keus 2007 27 67.95 2.4 6.5 81 1 or
2 per week/
10 weeks
Parallel Outpatient Physio
Klassen
2007
26 66.2 1.6 4.7 74 15-30 hrs/
12 weeks
Parallel Outpatient Exercise
Kurtais
2008
27 64.75 2.1 5 50 12 hrs/6
weeks
Parallel Outpatient Treadmill
Lehman
2005
11 75.8 6.5 73 5 per week/
2 weeks
Parallel Outpatient Cueing
Mak 2008 60 64 2.7 6 4-6 hrs/4
weeks
Parallel Outpatient Cueing/
Exercise
Marjama-
Lyons
2002
30 24 hrs/12
weeks
Parallel Outpatient Martial Arts
Meek
2010
39 64.2 4.9 79 12 weeks Parallel Outpatient Exercise
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Table 1. Key Characteristics of Studies (Continued)
Nieuw-
boer 2007
153 67.1 2.8 7.5 58 4.5 hrs/3
weeks
Cross-over Home Cueing
Protas
2005
18 72.5 2.9 7.6 100 24 hrs/8
weeks
Parallel Outpatient Treadmill
Purchas
2007
20 70 2.15 61 12 hrs/12
weeks
Cross-over Martial Arts
Sage 2009a 53 66 3.5 54 18-24 hrs/
10-12
weeks
Parallel Outpatient Exercise
Schenkman
1998
51 70.9 2.7 74 22.
5-30 hrs/10
weeks
Parallel Outpatient Exercise
Schilling
2008
18 59.2 2 61 2 per week/
8 weeks
Parallel Outpatient Exercise
Schmitz-
Hubsch
2006
56 63.5 5.8 77 16 hrs/24
weeks
Parallel Outpatient Martial Arts
Shankar
2008
28 66 2.4 7.7 50 18 hrs/12
weeks
Parallel Outpatient Cueing
Shankar
2009
20 8 hrs/8
weeks
Parallel Outpatient Treadmill
Stack 2012 47 12 hrs/4
weeks
Parallel Home Physio
Stozek
2003
61 65.5 2.3 4.5 48 56 hrs/4
weeks
Parallel Outpatient Exercise
Taheri
2011
24 40 hrs/ 10
weeks
Parallel Exercise
Talakad
2011
60 8 hrs/4
weeks
Parallel Outpatient Physio/
treadmill
Thaut
1996
37 71.3 2.5 7.7 70 10.5 hrs/3
weeks
Parallel Home Exercise/
Cueing
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WH A T ’ S N E W
Last assessed as up-to-date: 31 January 2012.
Date Event Description
16 April 2013 New citation required but conclusions have not
changed
New studies added, conclusions unchanged.
7 September 2012 New search has been performed Search updated to 31 January 2012.
New studies added, conclusions unchanged.
30 August 2011 New search has been performed Converted to new review format.
Updated search till 31 December 2010.
New studies, conclusions changed.
H I S T O R Y
Protocol first published: Issue 4, 2000
Review first published: Issue 3, 2001
Date Event Description
14 March 2001 New citation required and conclusions have changed Substantive amendment
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